Vincenzo Di Marzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3108948/publications.pdf

Version: 2024-02-01

776 papers 80,228 citations

140 h-index 244 g-index

793 all docs

793 docs citations

times ranked

793

33365 citing authors

#	Article	IF	CITATIONS
1	Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 1999, 400, 452-457.	27.8	2,022
2	The endogenous cannabinoid system controls extinction of aversive memories. Nature, 2002, 418, 530-534.	27.8	1,603
3	Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature, 2001, 410, 822-825.	27.8	1,468
4	Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 1994, 372, 686-691.	27.8	1,462
5	International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB ₁ and CB ₂ . Pharmacological Reviews, 2010, 62, 588-631.	16.0	1,425
6	Identification and Functional Characterization of Brainstem Cannabinoid CB ₂ Receptors. Science, 2005, 310, 329-332.	12.6	1,357
7	CB1 Cannabinoid Receptors and On-Demand Defense Against Excitotoxicity. Science, 2003, 302, 84-88.	12.6	1,083
8	Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. British Journal of Pharmacology, 2001, 134, 845-852.	5.4	945
9	Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. Journal of Cell Biology, 2003, 163, 463-468.	5. 2	923
10	The endocannabinoid system and its therapeutic exploitation. Nature Reviews Drug Discovery, 2004, 3, 771-784.	46.4	879
11	An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 8400-8405.	7.1	874
12	Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia, 2014, 55, 791-802.	5.1	766
13	Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends in Pharmacological Sciences, 2009, 30, 515-527.	8.7	717
14	Targeting the endocannabinoid system: to enhance or reduce?. Nature Reviews Drug Discovery, 2008, 7, 438-455.	46.4	701
15	Effects of cannabinoids and cannabinoidâ€enriched <i>Cannabis</i> extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology, 2011, 163, 1479-1494.	5.4	700
16	Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2â€arachidonoyl glycerol. British Journal of Pharmacology, 2002, 136, 550-557.	5.4	674
17	Endocannabinoid control of food intake and energy balance. Nature Neuroscience, 2005, 8, 585-589.	14.8	663
18	Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends in Neurosciences, 1998, 21, 521-528.	8.6	635

#	Article	IF	Citations
19	Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and \hat{l}^2 -Pancreatic Cells and in Obesity and Hyperglycemia. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3171-3180.	3.6	604
20	Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nature Reviews Neurology, 2020, 16, 9-29.	10.1	564
21	Endocannabinoid signaling at the periphery: 50 years after THC. Trends in Pharmacological Sciences, 2015, 36, 277-296.	8.7	524
22	Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain. Molecular Pharmacology, 2001, 60, 155-163.	2.3	523
23	An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. European Journal of Pharmacology, 1998, 353, 23-31.	3.5	515
24	Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1375-1387.	2.5	466
25	The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders. Cell Metabolism, 2013, 17, 475-490.	16.2	441
26	Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience, 2006, 139, 1405-1415.	2.3	434
27	Endocannabinoids. European Journal of Pharmacology, 1998, 359, 1-18.	3.5	432
28	Are cannabidiol and Î" ⁹ â€ŧetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. British Journal of Pharmacology, 2015, 172, 737-753.	5.4	412
29	The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology, 2004, 141, 765-774.	5.4	400
30	Endocannabinoids control spasticity in a multiple sclerosis model. FASEB Journal, 2001, 15, 300-302.	0.5	371
31	The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 8375-8380.	7.1	364
32	Levels, Metabolism, and Pharmacological Activity of Anandamide in CB ₁ Cannabinoid Receptor Knockout Mice. Journal of Neurochemistry, 2000, 75, 2434-2444.	3.9	355
33	Biochemistry and pharmacology of endovanilloids. , 2007, 114, 13-33.		349
34	New approaches and challenges to targeting the endocannabinoid system. Nature Reviews Drug Discovery, 2018, 17, 623-639.	46.4	346
35	Biosynthesis, Uptake, and Degradation of Anandamide and Palmitoylethanolamide in Leukocytes. Journal of Biological Chemistry, 1997, 272, 3315-3323.	3.4	342
36	Endovanilloids. FEBS Journal, 2004, 271, 1827-1834.	0.2	342

#	Article	IF	CITATIONS
37	Intense exercise increases circulating endocannabinoid and BDNF levels in humansâ€"Possible implications for reward and depression. Psychoneuroendocrinology, 2012, 37, 844-851.	2.7	340
38	Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. International Journal of Obesity, 2007, 31, 692-699.	3.4	339
39	Endocannabinoids and the control of energy balance. Trends in Endocrinology and Metabolism, 2007, 18, 27-37.	7.1	328
40	The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacological Research, 2009, 60, 77-84.	7.1	326
41	Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Letters, 2000, 483, 52-56.	2.8	320
42	The Activity of Anandamide at Vanilloid VR1 Receptors Requires Facilitated Transport across the Cell Membrane and Is Limited by Intracellular Metabolism. Journal of Biological Chemistry, 2001, 276, 12856-12863.	3.4	320
43	From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology. Physiological Reviews, 2016, 96, 1593-1659.	28.8	317
44	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351, 817-824.	3.7	315
45	Endocannabinoid signalling and the deteriorating brain. Nature Reviews Neuroscience, 2015, 16, 30-42.	10.2	312
46	N-Oleoyldopamine, a Novel Endogenous Capsaicin-like Lipid That Produces Hyperalgesia. Journal of Biological Chemistry, 2003, 278, 13633-13639.	3. 4	303
47	Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System. Science, 2007, 316, 1494-1497.	12.6	302
48	Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability. ACS Chemical Neuroscience, 2014, 5, 1131-1141.	3 . 5	301
49	Identification of a New Class of Molecules, the Arachidonyl Amino Acids, and Characterization of One Member That Inhibits Pain. Journal of Biological Chemistry, 2001, 276, 42639-42644.	3.4	297
50	Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB Journal, 2000, 14, 1432-1438.	0.5	292
51	Brain Regional Distribution of Endocannabinoids: Implications for Their Biosynthesis and Biological Function. Biochemical and Biophysical Research Communications, 1999, 256, 377-380.	2.1	288
52	†Endocannabinoids†and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Lipids and Lipid Metabolism, 1998, 1392, 153-175.	2.6	285
53	Plant-Derived Cannabinoids Modulate the Activity of Transient Receptor Potential Channels of Ankyrin Type-1 and Melastatin Type-8. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 1007-1015.	2.5	283
54	The Endocannabinoid System and its Modulation by Phytocannabinoids. Neurotherapeutics, 2015, 12, 692-698.	4.4	281

#	Article	IF	CITATIONS
55	Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Progress in Lipid Research, 2016, 62, 107-128.	11.6	276
56	Endovanilloid signaling in pain. Current Opinion in Neurobiology, 2002, 12, 372-379.	4.2	270
57	Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. Nature Communications, 2017, 8, 13958.	12.8	265
58	Biosynthesis and inactivation of the endocannabinoid 2â€erachidonoylglycerol in circulating and tumoral macrophages. FEBS Journal, 1999, 264, 258-267.	0.2	264
59	Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8760-8765.	7.1	263
60	Elevation of Endocannabinoid Levels in the Ventrolateral Periaqueductal Grey through Inhibition of Fatty Acid Amide Hydrolase Affects Descending Nociceptive Pathways via Both Cannabinoid Receptor Type 1 and Transient Receptor Potential Vanilloid Type-1 Receptors. Journal of Pharmacology and Experimental Therapeutics, 2006, 316, 969-982.	2.5	260
61	Endocannabinoids and the regulation of their levels in health and disease. Current Opinion in Lipidology, 2007, 18, 129-140.	2.7	257
62	Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochemical Journal, 1997, 322, 671-677.	3.7	254
63	Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research, 2002, 954, 73-81.	2.2	253
64	Possible endocannabinoid control of colorectal cancer growth. Gastroenterology, 2003, 125, 677-687.	1.3	252
65	Role in Anxiety Behavior of the Endocannabinoid System in the Prefrontal Cortex. Cerebral Cortex, 2008, 18, 1292-1301.	2.9	252
66	Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science, 2017, 356, 1084-1087.	12.6	251
67	The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology, 2003, 480, 133-150.	3.5	249
68	Analysis of cannabinoid receptor binding and mRNA expression and endogenous cannabinoid contents in the developing rat brain during late gestation and early postnatal period. Synapse, 1999, 33, 181-191.	1.2	247
69	Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiologica, 2012, 204, 255-266.	3.8	246
70	Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice. Brain, Behavior, and Immunity, 2018, 67, 230-245.	4.1	246
71	Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation1. Endocrinology, 2000, 141, 118-126.	2.8	245
72	Blood Levels of the Endocannabinoid Anandamide are Increased in Anorexia Nervosa and in Binge-Eating Disorder, but not in Bulimia Nervosa. Neuropsychopharmacology, 2005, 30, 1216-1221.	5.4	245

#	Article	IF	Citations
73	The endocannabinoid system in obesity and type 2 diabetes. Diabetologia, 2008, 51, 1356-1367.	6.3	245
74	Why do cannabinoid receptors have more than one endogenous ligand? Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3216-3228.	4.0	241
75	Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding <i>N</i> -acylethanolamines in piglets. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 6402-6406.	7.1	240
76	Anandamide receptors. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 377-391.	2.2	237
77	Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors. Journal of Neuroscience, 2003, 23, 3136-3144.	3.6	237
78	Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 2013, 85, 1306-1316.	4.4	237
79	Prefrontal Cortex Stimulation Induces 2-Arachidonoyl-Glycerol-Mediated Suppression of Excitation in Dopamine Neurons. Journal of Neuroscience, 2004, 24, 10707-10715.	3.6	232
80	Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids in Health and Disease, 2003, 2, 5.	3.0	228
81	Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB Journal, 2000, 14, 1432-1438.	0.5	227
82	The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. British Journal of Pharmacology, 2017, 174, 1349-1365.	5 . 4	227
83	Endocannabinoids: synthesis and degradation. Reviews of Physiology, Biochemistry and Pharmacology, 2006, 160, 1-24.	1.6	221
84	Cannabinoid CB ₁ â€receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. British Journal of Pharmacology, 2001, 134, 563-570.	5 . 4	219
85	The Palmitoylethanolamide and Oleamide Enigmas: Are These Two Fatty Acid Amides Cannabimimetic?. Current Medicinal Chemistry, 1999, 6, 757-773.	2.4	218
86	Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. British Journal of Pharmacology, 2001, 132, 631-640.	5.4	214
87	Anandamide: some like it hot. Trends in Pharmacological Sciences, 2001, 22, 346-349.	8.7	213
88	Mechanisms of the Anti-Obesity Effects of Oxytocin in Diet-Induced Obese Rats. PLoS ONE, 2011, 6, e25565.	2.5	211
89	Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO Journal, 2005, 24, 3026-3037.	7.8	210
90	Endocannabinoids May Mediate the Ability of (n-3) Fatty Acids to Reduce Ectopic Fat and Inflammatory Mediators in Obese Zucker Rats. Journal of Nutrition, 2009, 139, 1495-1501.	2.9	210

#	Article	IF	CITATIONS
91	Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology, 2007, 52, 415-422.	4.1	209
92	New perspectives on enigmatic vanilloid receptors. Trends in Neurosciences, 2000, 23, 491-497.	8.6	207
93	Cannabinoid CB1 Receptor Mediates Fear Extinction via Habituation-Like Processes. Journal of Neuroscience, 2006, 26, 6677-6686.	3.6	204
94	An introduction to the endocannabinoid system: from the early to the latest concepts. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, 1-15.	4.7	203
95	Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochemical Journal, 1996, 316, 977-984.	3.7	198
96	Upâ€regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB Journal, 2006, 20, 568-570.	0.5	198
97	The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochemical Journal, 1998, 331, 15-19.	3.7	195
98	The vanilloid receptor (VR1)â€mediated effects of anandamide are potently enhanced by the cAMPâ€dependent protein kinase. Journal of Neurochemistry, 2001, 77, 1660-1663.	3.9	191
99	Endocannabinoids and \hat{l}^2 -amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cellular and Molecular Life Sciences, 2006, 63, 1410-1424.	5.4	191
100	A role for endocannabinoids in the generation of parkinsonism and levodopaâ€induced dyskinesia in MPTPâ€iesioned nonâ€human primate models of Parkinson's disease. FASEB Journal, 2005, 19, 1140-1142.	0.5	189
101	Endocannabinoid system and mood disorders: Priming a target for new therapies. , 2013, 138, 18-37.		187
102	Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Letters, 2001, 506, 253-256.	2.8	186
103	The endocannabinoid signalling system: Biochemical aspects. Pharmacology Biochemistry and Behavior, 2005, 81, 224-238.	2.9	185
104	Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma â€~anandamide amidohydrolase'. FEBS Letters, 1995, 377, 82-86.	2.8	184
105	Endocannabinoids as Regulators of Transient Receptor Potential (TRP)Channels: a Further Opportunity to Develop New Endocannabinoid-Based Therapeutic Drugs. Current Medicinal Chemistry, 2010, 17, 1430-1449.	2.4	184
106	Unsaturated Long-Chain N-Acyl-vanillyl-amides (N-AVAMs): Vanilloid Receptor Ligands That Inhibit Anandamide-Facilitated Transport and Bind to CB1 Cannabinoid Receptors. Biochemical and Biophysical Research Communications, 1999, 262, 275-284.	2.1	183
107	Anxiolytic Effects in Mice of a Dual Blocker of Fatty Acid Amide Hydrolase and Transient Receptor Potential Vanilloid Type-1 Channels. Neuropsychopharmacology, 2009, 34, 593-606.	5.4	182
108	Non-CB1, Non-CB2 Receptors for Endocannabinoids, Plant Cannabinoids, and Synthetic Cannabimimetics: Focus on G-protein-coupled Receptors and Transient Receptor Potential Channels. Journal of NeuroImmune Pharmacology, 2010, 5, 103-121.	4.1	182

#	Article	IF	Citations
109	Analgesic actions of N -arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. British Journal of Pharmacology, 2007, 150, 766-781.	5.4	178
110	The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB Journal, 2008, 22, 285-294.	0.5	178
111	Anandamide Uptake by Human Endothelial Cells and Its Regulation by Nitric Oxide. Journal of Biological Chemistry, 2000, 275, 13484-13492.	3.4	175
112	Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochemical Journal, 2001, 358, 249-255.	3.7	174
113	Inhibitory effects of cannabinoid CB 1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB Journal, 2003, 17, 1771-1773.	0.5	173
114	Changes in plasma endocannabinoid levels in viscerally obese men following a 1Âyear lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia, 2009, 52, 213-217.	6.3	173
115	Arachidonoylserotonin and Other Novel Inhibitors of Fatty Acid Amide Hydrolase. Biochemical and Biophysical Research Communications, 1998, 248, 515-522.	2.1	172
116	Sex Steroid Influence on Cannabinoid CB1 Receptor mRNA and Endocannabinoid Levels in the Anterior Pituitary Gland. Biochemical and Biophysical Research Communications, 2000, 270, 260-266.	2.1	172
117	Endocannabinoid Dysregulation in the Pancreas and Adipose Tissue of Mice Fed With a Highâ€fat Diet. Obesity, 2008, 16, 553-565.	3.0	172
118	Phytocannabinoids beyond the <i>Cannabis</i> plant – do they exist?. British Journal of Pharmacology, 2010, 160, 523-529.	5.4	169
119	Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology, 2002, 123, 227-234.	1.3	167
120	Non‶HC cannabinoids inhibit prostate carcinoma growth ⟨i⟩in vitro⟨ i⟩ and ⟨i⟩in vivo⟨ i⟩: proâ€apoptotic effects and underlying mechanisms. British Journal of Pharmacology, 2013, 168, 79-102.	5.4	166
121	Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology, 2001, 60, 155-63.	2.3	166
122	Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: Potential use in companion animals. Veterinary Journal, 2007, 173, 21-30.	1.7	165
123	The  headache tree' via umbellulone and TRPA1 activates the trigeminovascular system. Brain, 2012, 135, 376-390.	7.6	163
124	Targeting the endocannabinoid system in cancer therapy: A call for further research. Nature Medicine, 2002, 8, 547-550.	30.7	161
125	Neural precursor cells induce cell death of high-grade astrocytomas through stimulation of TRPV1. Nature Medicine, 2012, 18, 1232-1238.	30.7	159
126	Presence and regulation of the endocannabinoid system in human dendritic cells. FEBS Journal, 2002, 269, 3771-3778.	0.2	157

#	Article	IF	Citations
127	Plant, Synthetic, and Endogenous Cannabinoids in Medicine. Annual Review of Medicine, 2006, 57, 553-574.	12.2	156
128	Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. Journal of Molecular Medicine, 2009, 87, 1111-1121.	3.9	156
129	Combining Mass Spectrometric Metabolic Profiling with Genomic Analysis: A Powerful Approach for Discovering Natural Products from Cyanobacteria. Journal of Natural Products, 2015, 78, 1671-1682.	3.0	156
130	Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chemistry and Physics of Lipids, 2000, 108, 191-209.	3.2	154
131	Evolutionary origins of the endocannabinoid system. Gene, 2006, 370, 64-74.	2.2	153
132	Lipopolysaccharide Downregulates Fatty Acid Amide Hydrolase Expression and Increases Anandamide Levels in Human Peripheral Lymphocytes. Archives of Biochemistry and Biophysics, 2001, 393, 321-328.	3.0	152
133	Tonic Endovanilloid Facilitation of Glutamate Release in Brainstem Descending Antinociceptive Pathways. Journal of Neuroscience, 2007, 27, 13739-13749.	3.6	152
134	The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. International Journal of Obesity, 2009, 33, S18-S24.	3.4	152
135	Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. Neuroscience, 1999, 92, 377-387.	2.3	150
136	Adolescent exposure to THC in female rats disrupts developmental changes in the prefrontal cortex. Neurobiology of Disease, 2015, 73, 60-69.	4.4	150
137	Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochemical Pharmacology, 2003, 65, 1473-1481.	4.4	149
138	Anandamide inhibits adhesion and migration of breast cancer cells. Experimental Cell Research, 2006, 312, 363-373.	2.6	149
139	Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight. Nature Neuroscience, 2011, 14, 9-15.	14.8	147
140	Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. Journal of Molecular Medicine, 2012, 90, 925-934.	3.9	146
141	Anandamide, an endogenous cannabinomimetic eicosanoid:  Killing two birds with one stone'. Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, 1-11.	2.2	145
142	Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Letters, 1999, 463, 235-240.	2.8	145
143	Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Molecular and Cellular Endocrinology, 2008, 286, S66-S78.	3.2	145
144	TRPV1 Receptors in the Central Nervous System: Potential for Previously Unforeseen Therapeutic Applications. Current Pharmaceutical Design, 2008, 14, 42-54.	1.9	145

#	Article	IF	CITATIONS
145	Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ ⁹ â€Tetrahydrocannabinolâ€Tolerant Rats. Journal of Neurochemistry, 2000, 74, 1627-1635.	3.9	144
146	Endocannabinoids in Amygdala and Nucleus Accumbens Mediate Social Play Reward in Adolescent Rats. Journal of Neuroscience, 2012, 32, 14899-14908.	3.6	144
147	Interactions between synthetic vanilloids and the endogenous cannabinoid system. FEBS Letters, 1998, 436, 449-454.	2.8	143
148	An NMR Spectroscopic Method to Identify and Classify Thiol†Trapping Agents: Revival of Michael Acceptors for Drug Discovery?. Angewandte Chemie - International Edition, 2011, 50, 467-471.	13.8	143
149	Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice. FASEB Journal, 2006, 20, 1003-1005.	0.5	142
150	Phosphatidic Acid as the Biosynthetic Precursor of the Endocannabinoid 2-Arachidonoylglycerol in Intact Mouse Neuroblastoma Cells Stimulated with Ionomycin. Journal of Neurochemistry, 2008, 72, 2113-2119.	3.9	142
151	N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating both Cannabinoid and Vanilloid Receptors. Neuropsychopharmacology, 2007, 32, 298-308.	5.4	141
152	Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and reâ€feeding. British Journal of Pharmacology, 2009, 158, 451-461.	5.4	141
153	A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB Journal, 2004, 18, 1606-1608.	0.5	140
154	Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): Effect of cAMP, cannabinoid CB1 receptors and endovanilloids. Experimental Cell Research, 2007, 313, 1911-1920.	2.6	140
155	Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. British Journal of Pharmacology, 2007, 151, 1109-1116.	5.4	138
156	Hedonic Eating Is Associated with Increased Peripheral Levels of Ghrelin and the Endocannabinoid 2-Arachidonoyl-Glycerol in Healthy Humans: A Pilot Study. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E917-E924.	3.6	135
157	The cannabinoid <scp>TRPA1</scp> agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. British Journal of Pharmacology, 2013, 169, 213-229.	5.4	135
158	Cannabinoid Receptors and Endocannabinoids: Role in Neuroinflammatory and Neurodegenerative Disorders. CNS and Neurological Disorders - Drug Targets, 2010, 9, 564-573.	1.4	134
159	Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Journal of Neurochemistry, 2003, 84, 1097-1109.	3.9	133
160	Depolarization-induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2-arachidonoylglycerol. Journal of Physiology, 2006, 577, 263-280.	2.9	133
161	The endovanilloid/endocannabinoid system in human osteoclasts: Possible involvement in bone formation and resorption. Bone, 2009, 44, 476-484.	2.9	132
162	At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends in Pharmacological Sciences, 2012, 33, 331-340.	8.7	132

#	Article	IF	Citations
163	Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal antiâ€inflammatory agent. British Journal of Pharmacology, 2015, 172, 142-158.	5.4	132
164	Dual effect of cannabinoid CB 1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cellular and Molecular Life Sciences, 2003, 60, 607-616.	5.4	131
165	Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. Journal of Neurochemistry, 2005, 92, 1327-1339.	3.9	131
166	Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiology of Disease, 2005, 20, 207-217.	4.4	131
167	Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Neuropharmacology, 2005, 48, 1154-1163.	4.1	131
168	Inhibitory effect of cannabichromene, a major nonâ€psychotropic cannabinoid extracted from <i>Cannabis sativa</i> , on inflammationâ€induced hypermotility in mice. British Journal of Pharmacology, 2012, 166, 1444-1460.	5.4	131
169	Prostaglandin Ethanolamides (Prostamides): In Vitro Pharmacology and Metabolism. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 745-757.	2.5	130
170	Endocannabinoids Activate Transient Receptor Potential Vanilloid 1 Receptors to Reduce Hyperdopaminergia-Related Hyperactivity: Therapeutic Implications. Biological Psychiatry, 2006, 59, 508-515.	1.3	130
171	Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy. Diabetes, 2010, 59, 1046-1054.	0.6	130
172	N-palmitoyl-ethanolamine: Biochemistry and new therapeutic opportunities. Biochimie, 2010, 92, 724-727.	2.6	130
173	Nonâ€psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. British Journal of Pharmacology, 2011, 162, 584-596.	5.4	130
174	Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochemical Journal, 2004, 380, 265-272.	3.7	129
175	An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology, 2003, 125, 765-774.	1.3	128
176	Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2229-38.	7.1	128
177	Acute Neuronal Injury, Excitotoxicity, and the Endocannabinoid System. Molecular Neurobiology, 2002, 26, 317-346.	4.0	127
178	Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cellular and Molecular Life Sciences, 2004, 61, 945-950.	5. 4	127
179	Highly Selective CB1 Cannabinoid Receptor Ligands and Novel CB1/VR1 Vanilloid Receptor "Hybrid― Ligands. Biochemical and Biophysical Research Communications, 2001, 281, 444-451.	2.1	124
180	Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochemical Journal, 2001, 358, 249.	3.7	124

#	Article	IF	CITATIONS
181	Control by the endogenous cannabinoid system of ras oncogeneâ€dependent tumor growth. FASEB Journal, 2001, 15, 1-17.	0.5	123
182	Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutrition and Metabolism, 2011, 8, 51.	3.0	123
183	Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. European Heart Journal, 2011, 32, 1369-1378.	2.2	123
184	Protective Role of Cannabinoid Receptor Type 2 in a Mouse Model of Diabetic Nephropathy. Diabetes, 2011, 60, 2386-2396.	0.6	123
185	CB1 antagonists for obesity—what lessons have we learned from rimonabant?. Nature Reviews Endocrinology, 2009, 5, 633-638.	9.6	121
186	Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. PLoS ONE, 2014, 9, e89566.	2.5	121
187	Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis. FASEB Journal, 2005, 19, 1338-1340.	0.5	120
188	Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. International Journal of Obesity, 2006, 30, S7-S12.	3.4	119
189	Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2006, 1761, 205-212.	2.4	118
190	The endocannabinoid system and pivotal role of the CB ₂ receptor in mouse spermatogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 11131-11136.	7.1	118
191	Cannabimimetic Fatty Acid Derivatives: The Anandamide Family and Other 'Endocannabinoids'. Current Medicinal Chemistry, 1999, 6, 721-744.	2.4	118
192	Biosynthesis and Inactivation of N-Arachidonoylethanolamine (Anandamide) and N-Docosahexaenoylethanolamine in Bovine Retina. Archives of Biochemistry and Biophysics, 1999, 370, 300-307.	3.0	117
193	Anandamide Inhibits Nuclear Factor-κB Activation through a Cannabinoid Receptor-Independent Pathway. Molecular Pharmacology, 2003, 63, 429-438.	2.3	116
194	Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. European Journal of Pharmacology, 2001, 419, 207-214.	3.5	115
195	Endocannabinoids and Related Compounds: Walking Back and Forth between Plant Natural Products and Animal Physiology. Chemistry and Biology, 2007, 14, 741-756.	6.0	115
196	Fatty Acid Amide Hydrolase Controls Mouse Intestinal Motility In Vivo. Gastroenterology, 2005, 129, 941-951.	1.3	114
197	Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 652-663.	2.5	114
198	Biochemistry of the Endogenous Ligands of Cannabinoid Receptors. Neurobiology of Disease, 1998, 5, 386-404.	4.4	113

#	Article	IF	CITATIONS
199	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351, 817.	3.7	113
200	Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. European Journal of Pharmacology, 2001, 420, 123-131.	3.5	113
201	Novel Inhibitors of Brain, Neuronal, and Basophilic Anandamide Amidohydrolase. Biochemical and Biophysical Research Communications, 1997, 231, 82-88.	2.1	112
202	The plant cannabinoid Δ ⁹ â€ŧetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. British Journal of Pharmacology, 2010, 160, 677-687.	5.4	112
203	Fatty Acid Amide Hydrolase, an Enzyme with Many Bioactive Substrates. Possible Therapeutic Implications. Current Pharmaceutical Design, 2002, 8, 533-547.	1.9	111
204	The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids. Handbook of Experimental Pharmacology, 2005, , 147-185.	1.8	111
205	Arvanil, anandamide and <i>N</i> à€arachidonoylâ€dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. European Journal of Neuroscience, 2007, 25, 2773-2782.	2.6	111
206	Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. Journal of Molecular Medicine, 2008, 86, 89-98.	3.9	108
207	The endocannabinoid system is modulated in response to spinal cord injury in rats. Neurobiology of Disease, 2009, 33, 57-71.	4.4	107
208	Comparative biology of the endocannabinoid system. FEBS Journal, 2000, 267, 4917-4927.	0.2	106
209	Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Molecular Brain, 2015, 8, 47.	2.6	106
210	The antiâ€inflammatory mediator palmitoylethanolamide enhances the levels of 2â€arachidonoylâ€glycerol and potentiates its actions at TRPV1 cation channels. British Journal of Pharmacology, 2016, 173, 1154-1162.	5.4	105
211	Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Letters, 2002, 513, 294-298.	2.8	104
212	Protective role of palmitoylethanolamide in contact allergic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 698-711.	5.7	104
213	Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. European Journal of Neuroscience, 2008, 28, 633-641.	2.6	103
214	Endocannabinoids and energy homeostasis: An update. BioFactors, 2014, 40, 389-397.	5.4	103
215	Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor. Scientific Reports, 2017, 7, 375.	3.3	103
216	Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain. Neuroscience, 2008, 151, 955-968.	2.3	102

#	Article	IF	Citations
217	Novel bioactive metabolites of dipyrone (metamizol). Bioorganic and Medicinal Chemistry, 2012, 20, 101-107.	3.0	102
218	A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends in Pharmacological Sciences, 2006, 27, 134-140.	8.7	101
219	Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. European Journal of Endocrinology, 2009, 161, 715-722.	3.7	100
220	Intestinal epithelial N-acylphosphatidylethanolamine phospholipase D links dietary fat to metabolic adaptations in obesity and steatosis. Nature Communications, 2019, 10, 457.	12.8	100
221	N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochemical Journal, 2000, 351 Pt 3, 817-24.	3.7	99
222	Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. Journal of Leukocyte Biology, 2016, 99, 531-540.	3.3	98
223	Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. British Journal of Pharmacology, 2001, 134, 945-950.	5.4	97
224	The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a highâ€fat diet. British Journal of Pharmacology, 2008, 153, 1272-1280.	5.4	97
225	Lipids as regulators of the activity of transient receptor potential type V1 (TRPV1) channels. Life Sciences, 2005, 77, 1651-1666.	4.3	96
226	FAAH and anandamide: is 2-AG really the odd one out?. Trends in Pharmacological Sciences, 2008, 29, 229-233.	8.7	96
227	Actions of two naturally occurring saturated N -acyldopamines on transient receptor potential vanilloid 1 (TRPV1) channels. British Journal of Pharmacology, 2004, 143, 251-256.	5.4	95
228	Finding of endocannabinoids in human eye tissues: Implications for glaucoma. Biochemical and Biophysical Research Communications, 2005, 330, 1062-1067.	2.1	95
229	Role and regulation of acylethanolamides in energy balance: focus on adipocytes and <i>β</i> à€eells. British Journal of Pharmacology, 2007, 152, 676-690.	5.4	95
230	Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes. Handbook of Experimental Pharmacology, 2011, , 75-104.	1.8	94
231	Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 52-60.	2.4	93
232	Editorial :. Recent Patents on CNS Drug Discovery, 2014, 9, 1-1.	0.9	93
233	In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. European Journal of Pharmacology, 2004, 484, 249-257.	3.5	92
234	Endocannabinoid overactivity and intestinal inflammation. Gut, 2006, 55, 1373-1376.	12.1	92

#	Article	IF	CITATIONS
235	FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Current Opinion in Investigational Drugs, 2010, 11, 51-62.	2.3	92
236	Biosynthesis and degradation of bioactive fatty acid amides in human breast cancer and rat pheochromocytoma cells. Implications for cell proliferation and differentiation. FEBS Journal, 1998, 254, 634-642.	0.2	91
237	Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. NeuroReport, 2001, 12, 2125-2129.	1.2	91
238	The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB Journal, 2002, 16, 1973-1975.	0.5	91
239	Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR- $\hat{1}\pm$ receptor activation in a genetic model of absence epilepsy. Neuropharmacology, 2013, 69, 115-126.	4.1	91
240	2-AG promotes the expression of conditioned fear via cannabinoid receptor type 1 on GABAergic neurons. Psychopharmacology, 2015, 232, 2811-2825.	3.1	91
241	Discovery of Prostamide F2 $\hat{l}\pm$ and Its Role in Inflammatory Pain and Dorsal Horn Nociceptive Neuron Hyperexcitability. PLoS ONE, 2012, 7, e31111.	2.5	91
242	Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. European Journal of Pharmacology, 2000, 396, 85-92.	3.5	90
243	Palmitoylethanolamide counteracts reactive astrogliosis induced by \hat{l}^2 -amyloid peptide. Journal of Cellular and Molecular Medicine, 2011, 15, 2664-2674.	3.6	90
244	Improvement in coronary circulatory function in morbidly obese individuals after gastric bypass-induced weight loss: relation to alterations in endocannabinoids and adipocytokines. European Heart Journal, 2013, 34, 2063-2073.	2.2	90
245	Arachidonic acid and eicosanoids as targets and effectors in second messenger interactions. Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, 239-254.	2.2	89
246	Protective activation of the endocannabinoid system during ischemia in dopamine neurons. Neurobiology of Disease, 2006, 24, 15-27.	4.4	89
247	Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutrition and Metabolism, 2011, 8, 7.	3.0	89
248	Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: Development, characterization and in vitro evaluation of their antitumoral efficacy. Journal of Controlled Release, 2012, 161, 927-932.	9.9	89
249	An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced Intestinal Inflammation and Hypermotility in the Mouse. Frontiers in Pharmacology, 2016, 7, 341.	3.5	89
250	Lifestyle and Metabolic Syndrome: Contribution of the Endocannabinoidome. Nutrients, 2019, 11, 1956.	4.1	89
251	TRPV1-Dependent and -Independent Alterations in the Limbic Cortex of Neuropathic Mice: Impact on Glial Caspases and Pain Perception. Cerebral Cortex, 2012, 22, 2495-2518.	2.9	88
252	Potential Biosynthetic Connections between the Two Cannabimimetic Eicosanoids, Anandamide and 2-Arachidonoyl-Glycerol, in Mouse Neuroblastoma Cells. Biochemical and Biophysical Research Communications, 1996, 227, 281-288.	2.1	87

#	Article	IF	Citations
253	Anandamide as an intracellular messenger regulating ion channel activity. Prostaglandins and Other Lipid Mediators, 2005, 77, 111-122.	1.9	87
254	The cannabinoid \hat{l} 9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity. Nutrition and Diabetes, 2013, 3, e68-e68.	3.2	87
255	Changes in endocannabinoid levels in a rat model of behavioural sensitization to morphine. European Journal of Neuroscience, 2004, 20, 1849-1857.	2.6	86
256	Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis—a difficult issue to handle. European Journal of Pharmacology, 2004, 492, 1-11.	3. 5	86
257	The A1 adenosine receptor as a new player in microglia physiology. Glia, 2014, 62, 122-132.	4.9	86
258	Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundamental and Clinical Pharmacology, 2002, 16, 297-302.	1.9	85
259	TRPV1 channels control synaptic plasticity in the developing superior colliculus. Journal of Physiology, 2009, 587, 2521-2535.	2.9	85
260	CB1 receptor antagonism: biological basis for metabolic effects. Drug Discovery Today, 2008, 13, 1026-1041.	6.4	84
261	Full Inhibition of Spinal FAAH Leads to TRPV1-Mediated Analgesic Effects in Neuropathic Rats and Possible Lipoxygenase-Mediated Remodeling of Anandamide Metabolism. PLoS ONE, 2013, 8, e60040.	2.5	84
262	A Structure/Activity Relationship Study on Arvanil, an Endocannabinoid and Vanilloid Hybrid. Journal of Pharmacology and Experimental Therapeutics, 2002, 300, 984-991.	2.5	83
263	Endocannabinoids in nervous system health and disease: the big picture in a nutshell. Philosophical Transactions of the Royal Society B: Biological Sciences, 2012, 367, 3193-3200.	4.0	83
264	Endocannabinoids: A unique opportunity to develop multitarget analgesics. Pain, 2013, 154, S87-S93.	4.2	83
265	ldentification of Endocannabinoids and Related Compounds in Human Fat Cells. Obesity, 2007, 15, 837-845.	3.0	82
266	An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis. Neurobiology of Disease, 2010, 37, 166-176.	4.4	82
267	Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochemical Pharmacology, 2005, 70, 446-452.	4.4	81
268	Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. International Journal of Neuropsychopharmacology, 2009, 12, 599.	2.1	81
269	The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. European Heart Journal, 2012, 33, 846-856.	2.2	81
270	Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2017, 45, 909-922.	3.7	81

#	Article	IF	CITATIONS
271	Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. European Journal of Pharmacology, 2002, 439, 83-92.	3.5	80
272	Genderâ€dependent cellular and biochemical effects of maternal deprivation on the hippocampus of neonatal rats: A possible role for the endocannabinoid system. Developmental Neurobiology, 2008, 68, 1334-1347.	3.0	80
273	Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease. Neurochemistry International, 2008, 52, 307-313.	3.8	80
274	Germ-free mice exhibit profound gut microbiota-dependent alterations of intestinal endocannabinoidome signaling. Journal of Lipid Research, 2020, 61, 70-85.	4.2	80
275	Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. European Journal of Neuroscience, 2006, 24, 2011-2020.	2.6	78
276	Palmitoylethanolamide normalizes intestinal motility in a model of postâ€inflammatory accelerated transit: involvement of <scp>CB</scp> ₁ receptors and <scp>TRPV</scp> 1 channels. British Journal of Pharmacology, 2014, 171, 4026-4037.	5.4	78
277	Identification of Endocannabinoids and Cannabinoid CB ₁ Receptor mRNA in the Pituitary Gland. Neuroendocrinology, 1999, 70, 137-145.	2.5	78
278	A Gradient of 2-Arachidonoylglycerol Regulates Mouse Epididymal Sperm Cell Start-Up1. Biology of Reproduction, 2010, 82, 451-458.	2.7	77
279	Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin Paracentrotus lividus. Lipids and Lipid Metabolism, 1997, 1345, 338-348.	2.6	76
280	Tetrahydrolipstatin Analogues as Modulators of Endocannabinoid 2-Arachidonoylglycerol Metabolism. Journal of Medicinal Chemistry, 2008, 51, 6970-6979.	6.4	76
281	Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. International Dairy Journal, 2010, 20, 231-235.	3.0	76
282	Altered gut microbiota and endocannabinoid system tone in vitamin D deficiency-mediated chronic pain. Brain, Behavior, and Immunity, 2020, 85, 128-141.	4.1	76
283	Suppression of Nerve Growth Factor Trk Receptors and Prolactin Receptors by Endocannabinoids Leads to Inhibition of Human Breast and Prostate Cancer Cell Proliferation. Endocrinology, 2000, 141, 118-126.	2.8	76
284	Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. European Journal of Pharmacology, 2000, 406, 363-374.	3.5	75
285	The Levels of the Endocannabinoid Receptor CB2 and Its Ligand 2-Arachidonoylglycerol Are Elevated in Endometrial Carcinoma. Endocrinology, 2010, 151, 921-928.	2.8	75
286	The Blockade of the Transient Receptor Potential Vanilloid Type 1 and Fatty Acid Amide Hydrolase Decreases Symptoms and Central Sequelae in the Medial Prefrontal Cortex of Neuropathic Rats. Molecular Pain, 2011, 7, 1744-8069-7-7.	2.1	75
287	The endocannabinoid 2-AG controls skeletal muscle cell differentiation via CB1 receptor-dependent inhibition of K _v 7 channels. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E2472-81.	7.1	75
288	Biosynthesis and inactivation of endocannabinoids: Relevance to their proposed role as neuromodulators. Life Sciences, 1999, 65, 645-655.	4.3	74

#	Article	IF	CITATIONS
289	The endocannabinoid system in the brain of <i>Carassius auratus</i> and its possible role in the control of food intake. Journal of Neurochemistry, 2005, 95, 662-672.	3.9	74
290	Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. Prostaglandins Leukotrienes and Essential Fatty Acids, 2006, 75, 413-418.	2.2	74
291	A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology, 2006, 51, 557-565.	4.1	74
292	The Endocannabinoid 2-Arachidonoylglycerol Is Responsible for the Slow Self-Inhibition in Neocortical Interneurons. Journal of Neuroscience, 2008, 28, 13532-13541.	3.6	74
293	Peripheral effects of the endocannabinoid system in energy homeostasis: Adipose tissue, liver and skeletal muscle. Reviews in Endocrine and Metabolic Disorders, 2011, 12, 153-162.	5.7	74
294	The effect of cannabichromene on adult neural stem/progenitor cells. Neurochemistry International, 2013, 63, 432-437.	3.8	74
295	Genetic deletion of monoacylglycerol lipase leads to impaired cannabinoid receptor <scp>CB</scp> ₁ R signaling and anxietyâ€like behavior. Journal of Neurochemistry, 2015, 135, 799-813.	3.9	74
296	Metabolism of anandamide and 2-arachidonoylglycerol: An historical overview and some recent developments. Lipids, 1999, 34, S319-S325.	1.7	73
297	Changes in endocannabinoid contents in reward-related brain regions of alcohol-exposed rats, and their possible relevance to alcohol relapse. British Journal of Pharmacology, 2004, 143, 455-464.	5.4	73
298	Forebrain-Specific Inactivation of G q $/$ G 11 Family G Proteins Results in Age-Dependent Epilepsy and Impaired Endocannabinoid Formation. Molecular and Cellular Biology, 2006, 26, 5888-5894.	2.3	73
299	Development of an Activityâ€Based Probe and In Silico Design Reveal Highly Selective Inhibitors for Diacylglycerol Lipaseâ€Î± in Brain. Angewandte Chemie - International Edition, 2013, 52, 12081-12085.	13.8	73
300	Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. Journal of Hepatology, 2015, 62, 1382-1390.	3.7	73
301	At the Tip of an Iceberg: Prenatal Marijuana and Its Possible Relation to Neuropsychiatric Outcome in the Offspring. Biological Psychiatry, 2016, 79, e33-e45.	1.3	73
302	Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 447-449.	2.2	72
303	Opposing Control of Cannabinoid Receptor Stimulation on Amyloid- \hat{l}^2 -Induced Reactive Gliosis: In Vitro and in Vivo Evidence. Journal of Pharmacology and Experimental Therapeutics, 2007, 322, 1144-1152.	2.5	72
304	Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma \hat{l}^2 -cells. Experimental Cell Research, 2007, 313, 2993-3004.	2.6	72
305	Inhibitory effect of salvinorin A, from <i>Salvia divinorum</i> , on ileitisâ€induced hypermotility: crossâ€ŧalk between κâ€opioid and cannabinoid CB ₁ receptors. British Journal of Pharmacology, 2008, 155, 681-689.	5.4	72
306	Analysis of anandamide, an endogenous cannabinoid substance, and of other natural N-acylethanolamines. Prostaglandins Leukotrienes and Essential Fatty Acids, 1995, 53, 301-308.	2.2	71

#	Article	IF	CITATIONS
307	From endocannabinoid profiling to â€~endocannabinoid therapeutics'. Current Opinion in Chemical Biology, 2009, 13, 321-331.	6.1	71
308	Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients. Lipids in Health and Disease, 2010, 9, 43.	3.0	71
309	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 2. Synthesis and Structureâ^'Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo. Journal of Medicinal Chemistry, 2008, 51, 5075-5084.	6.4	70
310	Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opinion on Investigational Drugs, 2012, 21, 1309-1322.	4.1	70
311	"Redundancy―of Endocannabinoid Inactivation: New Challenges and Opportunities for Pain Control. ACS Chemical Neuroscience, 2012, 3, 356-363.	3.5	70
312	Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. Journal of Medicinal Chemistry, 2016, 59, 2612-2632.	6.4	70
313	The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic?. Current Medicinal Chemistry, 1999, 6, 757-73.	2.4	70
314	Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver International, 2010, 30, 816-825.	3.9	69
315	Coronary Vasomotor Control in Obesity and Morbid Obesity. JACC: Cardiovascular Imaging, 2012, 5, 805-815.	5. 3	69
316	The inhibition of 2-arachidonoyl-glycerol (2-AG) biosynthesis, rather than enhancing striatal damage, protects striatal neurons from malonate-induced death: a potential role of cyclooxygenase-2-dependent metabolism of 2-AG. Cell Death and Disease, 2013, 4, e862-e862.	6.3	69
317	Development of the First Ultra-Potent "Capsaicinoid―Agonist at Transient Receptor Potential Vanilloid Type 1 (TRPV1) Channels and Its Therapeutic Potential. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 561-570.	2.5	68
318	Effect of dietary fat on endocannabinoids and related mediators: Consequences on energy homeostasis, inflammation and mood. Molecular Nutrition and Food Research, 2010, 54, 82-92.	3.3	68
319	Orexin-A represses satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid signaling. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4759-4764.	7.1	68
320	Investigation of the structure/activity relationship of human calcitonin gene-related peptide (CGRP). Biochemical and Biophysical Research Communications, 1986, 134, 1306-1311.	2.1	67
321	The Role of the Endocannabinoid System in Alzheimers Disease: Facts and Hypotheses. Current Pharmaceutical Design, 2008, 14, 2299-2305.	1.9	67
322	Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis, 2009, 205, 433-441.	0.8	67
323	Altered endocannabinoid signalling after a high-fat diet in Apoe â°'/â^' mice: relevance to adipose tissue inflammation, hepatic steatosis and insulin resistance. Diabetologia, 2011, 54, 2900-2910.	6.3	67
324	Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. Lipids in Health and Disease, 2013, 12, 78.	3.0	67

#	Article	IF	CITATIONS
325	Bisphenol A Induces Fatty Liver by an Endocannabinoid-Mediated Positive Feedback Loop. Endocrinology, 2016, 157, 1751-1763.	2.8	67
326	Anandamide – the other side of the coin. Trends in Pharmacological Sciences, 2000, 21, 43-44.	8.7	66
327	The biosynthesis of N-arachidonoyl dopamine (NADA), a putative endocannabinoid and endovanilloid, via conjugation of arachidonic acid with dopamine. Prostaglandins Leukotrienes and Essential Fatty Acids, 2009, 81, 291-301.	2.2	66
328	Synthesis and biological evaluation of [6]-gingerol analogues as transient receptor potential channel TRPV1 and TRPA1 modulators. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 1674-1677.	2.2	66
329	The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis. Pharmacological Research, 2014, 87, 151-159.	7.1	66
330	Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents. Journal of Medicinal Chemistry, 2016, 59, 6387-6406.	6.4	66
331	Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. Molecular Human Reproduction, 2005, 11, 21-28.	2.8	65
332	Periaqueductal Gray Metabotropic Glutamate Receptor Subtype 7 and 8 Mediate Opposite Effects on Amino Acid Release, Rostral Ventromedial Medulla Cell Activities, and Thermal Nociception. Journal of Neurophysiology, 2007, 98, 43-53.	1.8	65
333	Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. Journal of Molecular Medicine, 2008, 86, 413-422.	3.9	65
334	Synthesis, Cannabinoid Receptor Affinity, and Molecular Modeling Studies of Substituted 1-Aryl-5-(1 <i>H</i> -pyrrol-1-yl)-1 <i>H</i> -pyrazole-3-carboxamides. Journal of Medicinal Chemistry, 2008, 51, 1560-1576.	6.4	65
335	Development of a potent inhibitor of 2-arachidonoylglycerol hydrolysis with antinociceptive activity in vivo. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2009, 1791, 53-60.	2.4	65
336	Basal and Fasting/Refeedingâ€regulated Tissue Levels of Endogenous PPARâ€Î± Ligands in Zucker Rats. Obesity, 2010, 18, 55-62.	3.0	65
337	The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. Neuropharmacology, 2014, 77, 313-324.	4.1	65
338	Cyercenes, novel polypropionate pyrones from the autotomizing mediterranean mollusc cyerce cristallina. Tetrahedron, 1991, 47, 5569-5576.	1.9	64
339	New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6505-6510.	2.2	64
340	Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. Journal of Molecular Medicine, 2007, 85, 523-530.	3.9	64
341	Cannabinoid receptor type 1 and 2 expression in the skin of healthy dogs and dogs with atopic dermatitis. American Journal of Veterinary Research, 2012, 73, 988-995.	0.6	64
342	Iron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica, 2014, 99, 1876-1884.	3.5	64

#	Article	IF	CITATIONS
343	The Sleep Inducing Factor Oleamide Is Produced by Mouse Neuroblastoma Cells. Biochemical and Biophysical Research Communications, 1997, 239, 473-479.	2.1	63
344	Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. British Journal of Pharmacology, 2003, 139, 1417-1424.	5.4	63
345	A structure–activity relationship study on N-arachidonoyl-amino acids as possible endogenous inhibitors of fatty acid amide hydrolase. Biochemical and Biophysical Research Communications, 2004, 314, 192-196.	2.1	63
346	Maternal Dietary Fat Determines Metabolic Profile and the Magnitude of Endocannabinoid Inhibition of the Stress Response in Neonatal Rat Offspring. Endocrinology, 2010, 151, 1685-1694.	2.8	63
347	The role of the endocannabinoid system in skeletal muscle and metabolic adaptations to exercise: potential implications for the treatment of obesity. Obesity Reviews, 2012, 13, 1110-1124.	6.5	63
348	Spinal anandamide produces analgesia in neuropathic rats: Possible CB1- and TRPV1-mediated mechanisms. Neuropharmacology, 2012, 62, 1746-1755.	4.1	63
349	A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2â€arachidonoylglycerol with potential antiâ€obesity effects. British Journal of Pharmacology, 2013, 169, 784-793.	5.4	63
350	Behavioral and molecular changes elicited by acute administration of SR141716 to Δ9-tetrahydrocannabinol-tolerant rats: an experimental model of cannabinoid abstinence. Drug and Alcohol Dependence, 2004, 74, 159-170.	3.2	62
351	Evidence for an endocannabinoid system in the central nervous system of the leech Hirudo medicinalis. Molecular Brain Research, 2001, 87, 145-159.	2.3	61
352	The 1,2,3â€Triazole Ring as a Peptido―and Olefinomimetic Element: Discovery of Click Vanilloids and Cannabinoids. Angewandte Chemie - International Edition, 2007, 46, 9312-9315.	13.8	61
353	Role of endocannabinoids and endovanilloids in Ca2+ signalling. Cell Calcium, 2009, 45, 611-624.	2.4	61
354	Bioactive Prenylogous Cannabinoid from Fiber Hemp (<i>Cannabis sativa</i>). Journal of Natural Products, 2011, 74, 2019-2022.	3.0	61
355	CB1 Cannabinoid Receptors Couple to Focal Adhesion Kinase to Control Insulin Release. Journal of Biological Chemistry, 2013, 288, 32685-32699.	3.4	61
356	The Taming of Capsaicin. Reversal of the Vanilloid Activity of N-Acylvanillamines by Aromatic lodination. Journal of Medicinal Chemistry, 2005, 48, 4663-4669.	6.4	60
357	New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis. British Journal of Pharmacology, 2006, 147, 83-91.	5.4	60
358	Cannabimovone, a Cannabinoid with a Rearranged Terpenoid Skeleton from Hemp. European Journal of Organic Chemistry, 2010, 2010, 2067-2072.	2.4	60
359	Acute Resistance Exercise Induces Antinociception by Activation of the Endocannabinoid System in Rats. Anesthesia and Analgesia, 2014, 119, 702-715.	2.2	60
360	Obesity Affects the Microbiota–Gut–Brain Axis and the Regulation Thereof by Endocannabinoids and Related Mediators. International Journal of Molecular Sciences, 2020, 21, 1554.	4.1	60

#	Article	IF	Citations
361	Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation. European Journal of Medicinal Chemistry, 2008, 43, 62-72.	5 . 5	59
362	Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology, 2019, 146, 212-221.	4.1	59
363	Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins and Other Lipid Mediators, 2000, 61, 43-61.	1.9	58
364	Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. Gut, 2006, 55, 946-953.	12.1	58
365	New <i>N</i> -Arachidonoylserotonin Analogues with Potential "Dual―Mechanism of Action against Pain. Journal of Medicinal Chemistry, 2007, 50, 6554-6569.	6.4	58
366	Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Frontiers in Pharmacology, 2018, 9, 249.	3.5	58
367	N-Acylvanillamides:  Development of an Expeditious Synthesis and Discovery of New Acyl Templates for Powerful Activation of the Vanilloid Receptor. Journal of Medicinal Chemistry, 2002, 45, 3739-3745.	6.4	57
368	The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacological Research, 2010, 61, 537-546.	7.1	57
369	Endocannabinoid regulation in white and brown adipose tissue following thermogenic activation. Journal of Lipid Research, 2016, 57, 464-473.	4.2	57
370	The hypothalamic levels of the endocannabinoid, anandamide, peak immediately before the onset of puberty in female rats. Life Sciences, 2002, 70, 1407-1414.	4.3	56
371	Antiâ€inflammatory Effect of Palmitoylethanolamide on Human Adipocytes. Obesity, 2009, 17, 431-438.	3.0	56
372	Levels of endocannabinoids and palmitoylethanolamide and their pharmacological manipulation in chronic granulomatous inflammation in rats. Pharmacological Research, 2010, 61, 321-328.	7.1	56
373	2-Arylbenzofuran-based molecules as multipotent Alzheimer's disease modifying agents. European Journal of Medicinal Chemistry, 2012, 58, 519-532.	5.5	56
374	The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus. Current Diabetes Reports, 2019, 19, 117.	4.2	56
375	Oxytoxins, bioactive molecules produced by the marine opisthobranch molluscOxynoe olivacea from a diet-derived precursor. Experientia, 1990, 46, 767-770.	1.2	55
376	Bioactive long chain N-acylethanolamines in five species of edible bivalve molluscs. Lipids and Lipid Metabolism, 1998, 1389, 101-111.	2.6	55
377	The Endocannabinoid System Protects Rat Glioma Cells Against HIV-1 Tat Protein-induced Cytotoxicity. Journal of Biological Chemistry, 2002, 277, 50348-50354.	3.4	55
378	Endocannabinoids Link Feeding State and Auditory Perception-Related Gene Expression. Journal of Neuroscience, 2004, 24, 10013-10021.	3.6	55

#	Article	IF	CITATIONS
379	The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy. Bone, 2011, 48, 997-1007.	2.9	55
380	Endocannabinoids and neuropathic pain: focus on neuron–glia and endocannabinoid–neurotrophin interactions. European Journal of Neuroscience, 2014, 39, 401-408.	2.6	55
381	The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients. Pharmacological Research, 2019, 149, 104464.	7.1	55
382	Identification and characterization of phytocannabinoids as novel dual PPARÎ \pm / \hat{l}^3 agonists by a computational and in vitro experimental approach. Biochimica Et Biophysica Acta - General Subjects, 2019, 1863, 586-597.	2.4	55
383	Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid CB1 Receptor. Journal of Medicinal Chemistry, 2012, 55, 5627-5631.	6.4	54
384	Rimonabant Precipitates Anxiety in Rats Withdrawn from Palatable Food: Role of the Central Amygdala. Neuropsychopharmacology, 2013, 38, 2498-2507.	5 . 4	54
385	Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacological Research, 2007, 56, 428-442.	7.1	53
386	A multi-target approach for pain treatment. Pain, 2015, 156, 890-903.	4.2	53
387	Pharmacological inhibition of MAGL attenuates experimental colon carcinogenesis. Pharmacological Research, 2017, 119, 227-236.	7.1	53
388	Semiplenamides Aâ^'C, Fatty Acid Amides from a Papua New Guinea Collection of the Marine CyanobacteriumLyngbyasemiplena. Journal of Natural Products, 2003, 66, 1364-1368.	3.0	52
389	Enhanced cognitive performance of dopamine D3 receptor "knock-out―mice in the step-through passive-avoidance test: Assessing the role of the endocannabinoid/endovanilloid systems. Pharmacological Research, 2010, 61, 531-536.	7.1	52
390	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Antihyperalgesic Effects in Mice. Journal of Medicinal Chemistry, 2011, 54, 5444-5453.	6.4	52
391	A <scp>TRPV</scp> 1â€toâ€secretagogin regulatory axis controls pancreatic βâ€cell survival by modulating protein turnover. EMBO Journal, 2017, 36, 2107-2125.	7.8	52
392	Rapid and Concomitant Gut Microbiota and Endocannabinoidome Response to Diet-Induced Obesity in Mice. MSystems, 2019, 4, .	3.8	52
393	Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. European Journal of Pharmacology, 2012, 676, 41-50.	3. 5	51
394	Deficiency of cannabinoid receptor of type 2 worsens renal functional and structural abnormalities in streptozotocin-induced diabetic mice. Kidney International, 2014, 86, 979-990.	5 . 2	51
395	Effects of nonâ€euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. British Journal of Pharmacology, 2019, 176, 1568-1584.	5.4	51
396	Functional Interaction Between TRPV1 and \hat{l} 4-Opioid Receptors in the Descending Antinociceptive Pathway Activates Glutamate Transmission and Induces Analgesia. Journal of Neurophysiology, 2009, 101, 2411-2422.	1.8	50

#	Article	IF	CITATIONS
397	The Endocannabinoid 2-Arachidonoyl-Glycerol Controls Odor Sensitivity in Larvae of Xenopus laevis. Journal of Neuroscience, 2010, 30, 8965-8973.	3.6	50
398	Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold. European Journal of Medicinal Chemistry, 2012, 52, 284-294.	5.5	50
399	Acute inhibition of diacylglycerol lipase blocks endocannabinoidâ€mediated retrograde signalling: evidence for onâ€demand biosynthesis of 2â€arachidonoylglycerol. Journal of Physiology, 2013, 591, 4765-4776.	2.9	50
400	Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity. European Journal of Nutrition, 2016, 55, 1799-1805.	3.9	50
401	Dietary fatty acid intake and gut microbiota determine circulating endocannabinoidome signaling beyond the effect of body fat. Scientific Reports, 2020, 10, 15975.	3.3	50
402	Aquatic invertebrates open up new perspectives in eicosanoid research: Biosynthesis and bioactivity. Prostaglandins Leukotrienes and Essential Fatty Acids, 1994, 51, 215-229.	2.2	49
403	Highly Selective, Reversible Inhibitor Identified by Comparative Chemoproteomics Modulates Diacylglycerol Lipase Activity in Neurons. Journal of the American Chemical Society, 2015, 137, 8851-8857.	13.7	49
404	2-Pentadecyl-2-Oxazoline, the Oxazoline of Pea, Modulates Carrageenan-Induced Acute Inflammation. Frontiers in Pharmacology, 2017, 8, 308.	3. 5	49
405	Occurrence and possible biological role of the endocannabinoid system in the sea squirt <i>Ciona intestinalis</i> . Journal of Neurochemistry, 2005, 93, 1141-1156.	3.9	48
406	The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization. Behavioural Brain Research, 2008, 187, 289-296.	2.2	48
407	Synthesis and Pharmacological Activity of a Potent Inhibitor of the Biosynthesis of the Endocannabinoid 2â€Arachidonoylglycerol. ChemMedChem, 2009, 4, 946-950.	3.2	48
408	Modulation of mouse gastrointestinal motility by allyl isothiocyanate, a constituent of cruciferous vegetables (<i>Brassicaceae</i>): evidence for TRPA1â€independent effects. British Journal of Pharmacology, 2012, 165, 1966-1977.	5.4	48
409	Chronic exposure to cannabinoids during adolescence causes longâ€lasting behavioral deficits in adult mice. Addiction Biology, 2017, 22, 1778-1789.	2.6	48
410	Endocannabinoid chemical biology: a tool for the development of novel therapies. Current Opinion in Chemical Biology, 2009, 13, 309-320.	6.1	47
411	Negative Regulation of Leptin-induced Reactive Oxygen Species (ROS) Formation by Cannabinoid CB1 Receptor Activation in Hypothalamic Neurons. Journal of Biological Chemistry, 2015, 290, 13669-13677.	3.4	47
412	Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with inÂvivo anti-inflammatory properties. European Journal of Medicinal Chemistry, 2019, 180, 154-170.	5.5	47
413	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney International, 2019, 96, 555-567.	5.2	47
414	The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology, 2008, 55, 1105-1113.	4.1	46

#	Article	IF	Citations
415	Synthesis and biological evaluation of new potential inhibitors of N-acylethanolamine hydrolyzing acid amidase. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 1210-1213.	2.2	46
416	CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin- $2(1 < i > H < i >)$ -one-3-carboxamides. Journal of Medicinal Chemistry, 2014, 57, 8777-8791.	6.4	46
417	Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer's Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline. Journal of Alzheimer's Disease, 2015, 46, 497-506.	2.6	46
418	The gut microbiome, endocannabinoids and metabolic disorders. Journal of Endocrinology, 2021, 248, R83-R97.	2.6	46
419	Possible Anandamide and Palmitoylethanolamide involvement in human stroke. Lipids in Health and Disease, 2010, 9, 47.	3.0	45
420	Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine. International Journal of Neuropsychopharmacology, 2011, 14, 17-28.	2.1	45
421	Kavalactones and the endocannabinoid system: The plant-derived yangonin is a novel CB1 receptor ligand. Pharmacological Research, 2012, 66, 163-169.	7.1	45
422	Orexin-A and Endocannabinoid Activation of the Descending Antinociceptive Pathway Underlies Altered Pain Perception in Leptin Signaling Deficiency. Neuropsychopharmacology, 2016, 41, 508-520.	5.4	45
423	Dose-Specific Effects of Di-Isononyl Phthalate on the Endocannabinoid System and on Liver of Female Zebrafish. Endocrinology, 2017, 158, 3462-3476.	2.8	45
424	Regulation of hypothalamic endocannabinoid levels by neuropeptides and hormones involved in food intake and metabolism: Insulin and melanocortins. Neuropharmacology, 2008, 54, 206-212.	4.1	44
425	Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. Neuropharmacology, 2008, 55, 1274-1279.	4.1	44
426	Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders. Journal of NeuroImmune Pharmacology, 2015, 10, 233-244.	4.1	44
427	Fetal endocannabinoids orchestrate the organization of pancreatic islet microarchitecture. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6185-94.	7.1	44
428	The effects of anandamide on memory consolidation in mice involve both D1and D2 dopamine receptors. Behavioural Pharmacology, 1997, 8, 707-712.	1.7	43
429	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structureâ^'Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands. Journal of Medicinal Chemistry, 2010, 53, 5915-5928.	6.4	43
430	Anandamide-derived Prostamide F2 \hat{l}_{\pm} Negatively Regulates Adipogenesis. Journal of Biological Chemistry, 2013, 288, 23307-23321.	3.4	43
431	Circulating endocannabinoids in insulin sensitive vs. Insulin resistant obese postmenopausal women. A MONET group study. Obesity, 2014, 22, 211-216.	3.0	43
432	Genetic and pharmacological regulation of the endocannabinoid CB1 receptor in Duchenne muscular dystrophy. Nature Communications, 2018, 9, 3950.	12.8	43

#	Article	IF	CITATIONS
433	Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacological Research, 2021, 164, 105357.	7.1	43
434	Beneficial Effects of Akkermansia muciniphila Are Not Associated with Major Changes in the Circulating Endocannabinoidome but Linked to Higher Mono-Palmitoyl-Glycerol Levels as New PPARα Agonists. Cells, 2021, 10, 185.	4.1	43
435	Design, Synthesis, and Binding Studies of New Potent Ligands of Cannabinoid Receptors. Journal of Medicinal Chemistry, 2005, 48, 7343-7350.	6.4	42
436	Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology, 2005, 49, 502-513.	4.1	42
437	Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism: Clinical and Experimental, 2010, 59, 734-741.	3.4	42
438	A reâ€evaluation of 9â€∢scp>HODE⟨/scp> activity at ⟨scp>TRPV⟨/scp>1 channels in comparison with anandamide: enantioselectivity and effects at other ⟨scp>TRP⟨/scp> channels and in sensory neurons. British Journal of Pharmacology, 2012, 167, 1643-1651.	5.4	42
439	Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis. European Journal of Pharmacology, 2016, 791, 669-674.	3.5	42
440	Dual therapy targeting the endocannabinoid system prevents experimental diabetic nephropathy. Nephrology Dialysis Transplantation, 2017, 32, 1655-1665.	0.7	42
441	CB1 receptor activation induces intracellular Ca2+ mobilization and 2-arachidonoylglycerol release in rodent spinal cord astrocytes. Scientific Reports, 2018, 8, 10562.	3.3	42
442	The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders. Dialogues in Clinical Neuroscience, 2020, 22, 259-269.	3.7	42
443	Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro. Journal of Molecular Medicine, 2007, 85, 1379-1392.	3.9	41
444	Analysis of the "endocannabinoidome―in peripheral tissues of obese Zucker rats. Prostaglandins Leukotrienes and Essential Fatty Acids, 2013, 89, 127-135.	2.2	41
445	Ultra-micronized palmitoylethanolamide rescues the cognitive decline-associated loss of neural plasticity in the neuropathic mouse entorhinal cortex-dentate gyrus pathway. Neurobiology of Disease, 2019, 121, 106-119.	4.4	41
446	High molecular weight polyacetylenes from Petrosia ficiformis: Further structural analysis and biological activity. Tetrahedron Letters, 1989, 30, 3563-3566.	1.4	40
447	Endocannabinoids: Some Like it Fat (and Sweet Too). Journal of Neuroendocrinology, 2008, 20, 100-109.	2.6	40
448	The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain. Neuroscience, 2008, 157 , $1-11$.	2.3	40
449	Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems. Neurobiology of Disease, 2009, 36, 70-80.	4.4	40
450	Platelet-Rich Plasma Exerts Antinociceptive Activity by a Peripheral Endocannabinoid-Related Mechanism. Tissue Engineering - Part A, 2013, 19, 2120-2129.	3.1	40

#	Article	IF	Citations
451	New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno–modulatory activity. European Journal of Medicinal Chemistry, 2015, 97, 10-18.	5 . 5	40
452	Adelmidrol, a palmitoylethanolamide analogue, reduces chronic inflammation in a carrageeninâ€granuloma model in rats. Journal of Cellular and Molecular Medicine, 2009, 13, 1086-1095.	3.6	39
453	Deranged endocannabinoid responses to hedonic eating in underweight and recently weight-restored patients with anorexia nervosa. American Journal of Clinical Nutrition, 2015, 101, 262-269.	4.7	39
454	Elevated Systemic Levels of Endocannabinoids and Related Mediators Across the Menstrual Cycle in Women With Endometriosis. Reproductive Sciences, 2016, 23, 1071-1079.	2.5	39
455	Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. Journal of Neuroinflammation, 2019, 16, 274.	7.2	39
456	Neuronal and glial alterations in the cerebellar cortex of maternally deprived rats: Gender differences and modulatory effects of two inhibitors of endocannabinoid inactivation. Developmental Neurobiology, 2008, 68, 1429-1440.	3.0	38
457	DAG Lipase Involvement in Depolarization-Induced Suppression of Inhibition: Does Endocannabinoid Biosynthesis Always Meet the Demand?. Neuroscientist, 2010, 16, 608-613.	3.5	38
458	The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?. ACS Medicinal Chemistry Letters, 2012, 3, 182-186.	2.8	38
459	Endocrine disruptors in the diet of male Sparus aurata: Modulation of the endocannabinoid system at the hepatic and central level by Di-isononyl phthalate and Bisphenol A. Environment International, 2018, 119, 54-65.	10.0	38
460	Cannabidivarin completely rescues cognitive deficits and delays neurological and motor defects in male <i>Mecp2</i> mutant mice. Journal of Psychopharmacology, 2019, 33, 894-907.	4.0	38
461	Three of a Kind: Control of the Expression of Liver-Expressed Antimicrobial Peptide 2 (LEAP2) by the Endocannabinoidome and the Gut Microbiome. Molecules, 2022, 27, 1.	3.8	38
462	Effect of maternal under-nutrition on pup body weight and hypothalamic endocannabinoid levels. Cellular and Molecular Life Sciences, 2003, 60, 382-389.	5.4	37
463	Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington's disease. Brain Research, 2005, 1050, 210-216.	2.2	37
464	The CB1 cannabinoid receptor antagonist AM251 attenuates amphetamine-induced behavioural sensitization while causing monoamine changes in nucleus accumbens and hippocampus. Pharmacology Biochemistry and Behavior, 2008, 89, 384-391.	2.9	37
465	Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain. Pharmacological Research, 2015, 91, 9-14.	7.1	37
466	N-Oleoyl-glycine reduces nicotine reward and withdrawal in mice. Neuropharmacology, 2019, 148, 320-331.	4.1	37
467	Endocannabinoids and related fatty acid amides, and their regulation, in the salivary glands of the lone star tick. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2003, 1633, 61-67.	2.4	36
468	Arvanil inhibits T lymphocyte activation and ameliorates autoimmune encephalomyelitis. Journal of Neuroimmunology, 2006, 171, 110-119.	2.3	36

#	Article	IF	CITATIONS
469	Rational Design, Synthesis, and Pharmacological Properties of New 1,8-Naphthyridin-2(1H)-on-3-Carboxamide Derivatives as Highly Selective Cannabinoid-2 Receptor Agonists. Journal of Medicinal Chemistry, 2009, 52, 3644-3651.	6.4	36
470	(â^')-Menthylamine derivatives as potent and selective antagonists of transient receptor potential melastatin type-8 (TRPM8) channels. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2729-2732.	2.2	36
471	Cannabinomimetic Lipid from a Marine Cyanobacterium. Journal of Natural Products, 2011, 74, 2313-2317.	3.0	36
472	Homology modeling in tandem with 3D-QSAR analyses: A computational approach to depict the agonist binding site of the human CB2 receptor. European Journal of Medicinal Chemistry, 2011, 46, 4489-4505.	5.5	36
473	Anticipatory and consummatory effects of (hedonic) chocolate intake are associated with increased circulating levels of the orexigenic peptide ghrelin and endocannabinoids in obese adults. Food and Nutrition Research, 2015, 59, 29678.	2.6	36
474	Therapy with a Selective Cannabinoid Receptor Type 2 Agonist Limits Albuminuria and Renal Injury in Mice with Type 2 Diabetic Nephropathy. Nephron, 2016, 132, 59-69.	1.8	36
475	Fish Oil, Cannabidiol and the Gut Microbiota: An Investigation in a Murine Model of Colitis. Frontiers in Pharmacology, 2020, 11, 585096.	3.5	36
476	Anticonvulsive Properties of Cannabidiol in a Model of Generalized Seizure Are Transient Receptor Potential Vanilloid 1 Dependent. Cannabis and Cannabinoid Research, 2020, 5, 145-149.	2.9	36
477	Altered dopamine D3 receptor gene expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment. Biochemical Pharmacology, 2020, 177, 114004.	4.4	36
478	Capsaicin-like effects of N-arachidonoyl-dopamine in the isolated guinea pig bronchi and urinary bladder. European Journal of Pharmacology, 2003, 475, 107-114.	3.5	35
479	Endocannabinoids Generated by Ca2+ or by Metabotropic Glutamate Receptors Appear to Arise from Different Pools of Diacylglycerol Lipase. PLoS ONE, 2011, 6, e16305.	2.5	35
480	3-Ylidenephthalides as a new class of transient receptor potential channel TRPA1 and TRPM8 modulators. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5614-5618.	2.2	35
481	Increased levels of palmitoylethanolamide and other bioactive lipid mediators and enhanced local mast cell proliferation in canine atopic dermatitis. BMC Veterinary Research, 2014, 10, 21.	1.9	35
482	The endocannabinoid system in renal cells: regulation of <scp><scp>Na</scp></scp> ⁺ transport by <scp>CB</scp> ₁ receptors through distinct cell signalling pathways. British Journal of Pharmacology, 2015, 172, 4615-4625.	5.4	35
483	Palmitoylethanolamide Supplementation during Sensitization Prevents Airway Allergic Symptoms in the Mouse. Frontiers in Pharmacology, 2017, 8, 857.	3.5	35
484	α-and γ-Pyrone-poly·propionates from the mediterranean ascoglossan mollusc ercolania funerea. Tetrahedron, 1992, 48, 9561-9566.	1.9	34
485	Diacylglycerol Lipase Is Not Involved in Depolarization-Induced Suppression of Inhibition at Unitary Inhibitory Connections in Mouse Hippocampus. Journal of Neuroscience, 2010, 30, 2710-2715.	3.6	34
486	Non-psychotropic analgesic drugs from the endocannabinoid system: "Magic bullet―or "multiple-target―strategies?. European Journal of Pharmacology, 2013, 716, 41-53.	3.5	34

#	Article	IF	Citations
487	Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors. Multiple Sclerosis Journal, 2013, 19, 1896-1904.	3.0	34
488	Inhibiting endocannabinoid biosynthesis: a novel approach to the treatment of constipation. British Journal of Pharmacology, 2015, 172, 3099-3111.	5.4	34
489	Polymorphism rs1761667 in the CD36 Gene Is Associated to Changes in Fatty Acid Metabolism and Circulating Endocannabinoid Levels Distinctively in Normal Weight and Obese Subjects. Frontiers in Physiology, 2017, 8, 1006.	2.8	34
490	Why endocannabinoids are not all alike. Nature Neuroscience, 2008, 11, 124-126.	14.8	33
491	Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 6806-6809.	2.2	33
492	Anandamide serves two masters in the brain. Nature Neuroscience, 2010, 13, 1446-1448.	14.8	33
493	Exploiting Nanotechnologies and TRPV1 Channels to Investigate the Putative Anandamide Membrane Transporter. PLoS ONE, 2010, 5, e10239.	2.5	33
494	The Cannabinoid Receptor Type 2 as Mediator of Mesenchymal Stromal Cell Immunosuppressive Properties. PLoS ONE, 2013, 8, e80022.	2.5	33
495	Cannabinoid properties of methylfluorophosphonate analogs. Journal of Pharmacology and Experimental Therapeutics, 2000, 294, 1209-18.	2.5	33
496	Minireview: Interactions between second messengers: Cyclic AMP and phospholipase A2- and phospholipase C-metabolites. Life Sciences, 1991, 49, 247-259.	4.3	32
497	Antinociceptive effects of tetrazole inhibitors of endocannabinoid inactivation: cannabinoid and nonâ€eannabinoid receptorâ€mediated mechanisms. British Journal of Pharmacology, 2008, 155, 775-782.	5.4	32
498	Brain TRPV1: a depressing TR(i)P down memory lane?. Trends in Pharmacological Sciences, 2008, 29, 594-600.	8.7	32
499	N-palmitoyl-vanillamide (palvanil) is a non-pungent analogue of capsaicin with stronger desensitizing capability against the TRPV1 receptor and anti-hyperalgesic activity. Pharmacological Research, 2011, 63, 294-299.	7.1	32
500	Inhibition of basal and ultraviolet B-induced melanogenesis by cannabinoid CB1 receptors: a keratinocyte-dependent effect. Archives of Dermatological Research, 2011, 303, 201-210.	1.9	32
501	Endocannabinoids: An appetite for fat. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12567-12568.	7.1	32
502	Inhibitors of endocannabinoid breakdown for pain: Not so FA(AH)cile, after all. Pain, 2012, 153, 1785-1786.	4.2	32
503	Taste sensitivity to 6-n-propylthiouracil is associated with endocannabinoid plasma levels in normal-weight individuals. Nutrition, 2013, 29, 531-536.	2.4	32
504	Pure Î" 9 -tetrahydrocannabivarin and a Cannabis sativa extract with high content in Î" 9 -tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. Pharmacological Research, 2016, 113, 199-208.	7.1	32

#	Article	IF	CITATIONS
505	Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility. Journal of Medicinal Chemistry. 2016, 59, 1052-1067.	6.4	32
506	Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment. European Journal of Medicinal Chemistry, 2019, 178, 243-258.	5.5	32
507	Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Current Medicinal Chemistry, 1999, 6, 721-44.	2.4	32
508	New tetrazole-based selective anandamide uptake inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2820-2824.	2.2	31
509	Anandamide and AM251, via water, modulate food intake at central and peripheral level in fish. General and Comparative Endocrinology, 2010, 166, 259-267.	1.8	31
510	Three-dimensional quantitative structure–selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2. European Journal of Medicinal Chemistry, 2011, 46, 547-555.	5.5	31
511	Effects of palmitoylethanolamide on the cutaneous allergic inflammatory response in Ascaris hypersensitive Beagle dogs. Veterinary Journal, 2012, 191, 377-382.	1.7	31
512	Effects of curcumin and curcumin analogues on TRP channels. Fìtoterapìâ, 2017, 122, 126-131.	2.2	31
513	Disruption of the gonadal endocannabinoid system in zebrafish exposed to diisononyl phthalate. Environmental Pollution, 2018, 241, 1-8.	7.5	31
514	Chemical characterisation of oxidative degradation products of \hat{l} 9-THC. Tetrahedron, 2010, 66, 9497-9501.	1.9	30
515	Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target―analgesics. Pharmacological Research, 2013, 76, 98-105.	7.1	29
516	Polypharmacology Shakes Hands with Complex Aetiopathology. Trends in Pharmacological Sciences, 2015, 36, 802-821.	8.7	29
517	Participants with Normal Weight or with Obesity Show Different Relationships of 6-n-Propylthiouracil (PROP) Taster Status with BMI and Plasma Endocannabinoids. Scientific Reports, 2017, 7, 1361.	3.3	29
518	Histological and biochemical bases of defense mechanisms in four species of Polybranchioidea ascoglossan molluscs. Marine Biology, 1993, 117, 367-380.	1.5	28
519	Discovery of Glycine Sulfonamides as Dual Inhibitors of $\langle i \rangle$ sn $\langle i \rangle$ -1-Diacylglycerol Lipase Î \pm and Î \pm /Î 2 -Hydrolase Domain 6. Journal of Medicinal Chemistry, 2014, 57, 6610-6622.	6.4	28
520	Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors. Journal of Medicinal Chemistry, 2015, 58, 5979-5988.	6.4	28
521	Protective Effect of Palmitoylethanolamide in a Rat Model of Cystitis. Journal of Urology, 2015, 193, 1401-1408.	0.4	28
522	Treatment with the GPR55 antagonist CID16020046 increases neutrophil activation in mouse atherogenesis. Thrombosis and Haemostasis, 2016, 116, 987-997.	3.4	28

#	Article	IF	CITATIONS
523	Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality. European Journal of Medicinal Chemistry, 2016, 122, 619-634.	5. 5	28
524	Life-long epigenetic programming of cortical architecture by maternal †Western†Meiet during pregnancy. Molecular Psychiatry, 2020, 25, 22-36.	7.9	28
525	A marine mollusc provides the first example of in vivo storage of prostaglandins: Prostaglandin-1,15-lactones. Experientia, 1991, 47, 56-60.	1.2	27
526	Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: Interactions with muscarinic and $\hat{\Gamma}$ -opioid receptors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2009, 1793, 1289-1303.	4.1	27
527	In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB2 receptor inverse agonists. Pharmacological Research, 2010, 61, 349-354.	7.1	27
528	Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation. Journal of Inflammation, 2011, 8, 33.	3.4	27
529	Design, Synthesis, and Pharmacological Characterization of Indol-3-ylacetamides, Indol-3-yloxoacetamides, and Indol-3-ylcarboxamides: Potent and Selective CB2 Cannabinoid Receptor Inverse Agonists. Journal of Medicinal Chemistry, 2012, 55, 5391-5402.	6.4	27
530	Investigations on the 4â€Quinoloneâ€3â€Carboxylic Acid Motif Partâ€5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoidâ€2 Receptor Ligands through a Bioisosteric Approach. ChemMedChem, 2012, 7, 920-934.	3.2	27
531	Circulating Endocannabinoids and the Polymorphism 385C>A in Fatty Acid Amide Hydrolase (FAAH) Gene May Identify the Obesity Phenotype Related to Cardiometabolic Risk: A Study Conducted in a Brazilian Population of Complex Interethnic Admixture. PLoS ONE, 2015, 10, e0142728.	2.5	27
532	Fishing for Targets of Alien Metabolites: A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Agonist from a Marine Pest. Marine Drugs, 2018, 16, 431.	4.6	27
533	The CB1/VR1 agonist arvanil induces apoptosis through an FADD/caspase-8-dependent pathway. British Journal of Pharmacology, 2003, 140, 1035-1044.	5.4	26
534	First "hybrid―ligands of vanilloid TRPV1 and cannabinoid CB2receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands. FEBS Letters, 2006, 580, 568-574.	2.8	26
535	Role of N-Arachidonoyl-Serotonin (AA-5-HT) in Sleep-Wake Cycle Architecture, Sleep Homeostasis, and Neurotransmitters Regulation. Frontiers in Molecular Neuroscience, 2017, 10, 152.	2.9	26
536	Endocannabinoid hydrolysis inhibition unmasks that unsaturated fatty acids induce a robust biosynthesis of 2â€arachidonoylâ€glycerol and its congeners in human myeloid leukocytes. FASEB Journal, 2020, 34, 4253-4265.	0.5	26
537	Effects of BPA on zebrafish gonads: Focus on the endocannabinoid system. Environmental Pollution, 2020, 264, 114710.	7.5	26
538	Cannabinoids and Schizophrenia: Therapeutic Prospects. Current Pharmaceutical Design, 2014, 20, 2194-2204.	1.9	26
539	Endocannabinoids, feeding and suckling – from our perspective. International Journal of Obesity, 2006, 30, S24-S28.	3.4	25
540	Modulation of thermo-transient receptor potential (thermo-TRP) channels by thymol-based compounds. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3535-3539.	2.2	25

#	Article	IF	CITATIONS
541	Role of Endocannabinoids and Cannabinoid-1 Receptors in Cerebrocortical Blood Flow Regulation. PLoS ONE, 2013, 8, e53390.	2.5	25
542	Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. European Journal of Medicinal Chemistry, 2016, 124, 17-35.	5.5	25
543	Important role of endocannabinoid signaling in the development of functional vision and locomotion in zebrafish. FASEB Journal, 2016, 30, 4275-4288.	0.5	25
544	Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease. European Journal of Medicinal Chemistry, 2019, 161, 239-251.	5.5	25
545	Manipulation of Dietary Amino Acids Prevents and Reverses Obesity in Mice Through Multiple Mechanisms That Modulate Energy Homeostasis. Diabetes, 2020, 69, 2324-2339.	0.6	25
546	Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors. European Journal of Medicinal Chemistry, 2012, 58, 30-43.	5.5	24
547	Sesquiterpenoids from Common Ragweed (<i>Ambrosia artemisiifolia</i> L.), an Invasive Biological Polluter. European Journal of Organic Chemistry, 2012, 2012, 5162-5170.	2.4	24
548	Effects of metabolites of the analgesic agent dipyrone (metamizol) on rostral ventromedial medulla cell activity in mice. European Journal of Pharmacology, 2015, 748, 115-122.	3.5	24
549	The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. Pharmacological Research, 2016, 111, 251-263.	7.1	24
550	Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis. Veterinary Journal, 2016, 207, 85-91.	1.7	24
551	Endovanilloid control of pain modulation by the rostroventromedial medulla in an animal model of diabetic neuropathy. Neuropharmacology, 2016, 107, 49-57.	4.1	24
552	CB 1 Cannabinoid Receptors Mediate Cognitive Deficits and Structural Plasticity Changes During Nicotine Withdrawal. Biological Psychiatry, 2017, 81, 625-634.	1.3	24
553	Characterization of endocannabinoids and related acylethanolamides in the synovial fluid of dogs with osteoarthritis: a pilot study. BMC Veterinary Research, 2017, 13, 309.	1.9	24
554	Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier. Frontiers in Endocrinology, 2019, 10, 219.	3.5	24
555	Mgll Knockout Mouse Resistance to Diet-Induced Dysmetabolism Is Associated with Altered Gut Microbiota. Cells, 2020, 9, 2705.	4.1	24
556	Gut feelings about the endocannabinoid system. Neurogastroenterology and Motility, 2011, 23, 391-398.	3.0	23
557	Overlapping Distribution of Orexin and Endocannabinoid Receptors and Their Functional Interaction in the Brain of Adult Zebrafish. Frontiers in Neuroanatomy, 2018, 12, 62.	1.7	23
558	Alterations of brain endocannabinoidome signaling in germ-free mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158786.	2.4	23

#	Article	IF	Citations
559	Development of the First Potential Covalent Inhibitors of Anandamide Cellular Uptake. Journal of Medicinal Chemistry, 2006, 49, 2320-2332.	6.4	22
560	The endocannabinoid and endovanilloid systems and their interactions in neuropathic pain. Drug Development Research, 2006, 67, 339-354.	2.9	22
561	The administration of endocannabinoid uptake inhibitors OMDM-2 or VDM-11 promotes sleep and decreases extracellular levels of dopamine in rats. Physiology and Behavior, 2013, 109, 88-95.	2.1	22
562	Some like it pungent and vile. TRPA1 as a molecular target for the malodorous vinyl disulfides from asafoetida. Fìtoterapìâ, 2013, 90, 247-251.	2.2	22
563	Exposure to Allergen Causes Changes in NTS Neural Activities after Intratracheal Capsaicin Application, in Endocannabinoid Levels and in the Glia Morphology of NTS. BioMed Research International, 2015, 2015, 1-10.	1.9	22
564	Formation of OX-1R/CB 1 R heteromeric complexes in embryonic mouse hypothalamic cells: Effect on intracellular calcium, 2-arachidonoyl-glycerol biosynthesis and ERK phosphorylation. Pharmacological Research, 2016, 111, 600-609.	7.1	22
565	Allodynia Lowering Induced by Cannabinoids and Endocannabinoids (ALICE). Pharmacological Research, 2017, 119, 272-277.	7.1	22
566	Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. British Journal of Pharmacology, 2018, 175, 4371-4385.	5.4	22
567	Systemic administration of serotonin exacerbates abdominal pain and colitis via interaction with the endocannabinoid system. Biochemical Pharmacology, 2019, 161, 37-51.	4.4	22
568	Orexin-A and endocannabinoids are involved in obesity-associated alteration of hippocampal neurogenesis, plasticity, and episodic memory in mice. Nature Communications, 2021, 12, 6137.	12.8	22
569	Expression and Functions of the CB2 Receptor in Human Leukocytes. Frontiers in Pharmacology, 2022, 13, 826400.	3.5	22
570	v-K- <i>ras</i> leads to preferential farnesylation of p21 <i> ^{ras} </i> in FRTL-5 cells: Multiple interference with the isoprenoid pathway. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 13646-13651.	7.1	21
571	The anandamide membrane transporter. Structure–activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region. Bioorganic and Medicinal Chemistry, 2004, 12, 5161-5169.	3.0	21
572	Evaluation of the endogenous cannabinoid system in mediating the behavioral effects of dipyrone (metamizol) in mice. Behavioural Pharmacology, 2012, 23, 722-726.	1.7	21
573	Analogues of perillaketone as highly potent agonists of TRPA1 channel. Food Chemistry, 2013, 141, 2044-2051.	8.2	21
574	Prostamide <scp>F₂</scp> _α receptor antagonism combined with inhibition of <scp>FAAH </scp> may block the proâ€inflammatory mediators formed following selective <scp>FAAH</scp> inhibition. British Journal of Pharmacology, 2014, 171, 1408-1419.	5.4	21
575	Peripheral Endocannabinoid Responses to Hedonic Eating in Binge-Eating Disorder. Nutrients, 2017, 9, 1377.	4.1	21
576	Efficacy of combined therapy with fish oil and phytocannabinoids in murine intestinal inflammation. Phytotherapy Research, 2021, 35, 517-529.	5.8	21

#	Article	IF	Citations
577	Endocannabinoid Modulation in the Olfactory Epithelium. Results and Problems in Cell Differentiation, 2011, 52, 139-145.	0.7	21
578	Oxyhomologues of Anandamide and Related Endolipids:Â Chemoselective Synthesis and Biological Activity. Journal of Medicinal Chemistry, 2006, 49, 2333-2338.	6.4	20
579	Desulfohaplosamate, a new phosphate-containing steroid from Dasychalina sp., is a selective cannabinoid CB2 receptor ligand. Steroids, 2011, 76, 998-1002.	1.8	20
580	Mooreamide A: A Cannabinomimetic Lipid from the Marine Cyanobacterium <i>Moorea bouillonii</i> Lipids, 2014, 49, 1127-1132.	1.7	20
581	Early Low-Fat Diet Enriched With Linolenic Acid Reduces Liver Endocannabinoid Tone and Improves Late Glycemic Control After a High-Fat Diet Challenge in Mice. Diabetes, 2016, 65, 1824-1837.	0.6	20
582	Effects of chronic exercise on the endocannabinoid system in Wistar rats with high-fat diet-induced obesity. Journal of Physiology and Biochemistry, 2016, 72, 183-199.	3.0	20
583	Design and Synthesis of New Transient Receptor Potential Vanilloid Type-1 (TRPV1) Channel Modulators: Identification, Molecular Modeling Analysis, and Pharmacological Characterization of the <i>N</i> -(4-Hydroxy-3-methoxybenzyl)-4-(thiophen-2-yl)butanamide, a Small Molecule Endowed with Agonist TRPV1 Activity and Protective Effects against Oxidative Stress. ACS Chemical Neuroscience,	3.5	20
584	2016, 7, 737-740. Antitumor effect of pyrrolo-1,5-benzoxazepine-15 and its synergistic effect with Oxaliplatin and 5-FU in colorectal cancer cells. Cancer Biology and Therapy, 2016, 17, 849-858.	3.4	20
585	Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor. European Journal of Pharmaceutical Sciences, 2017, 101, 1-10.	4.0	20
586	î"9-tetrahydrocannabivarin impairs epithelial calcium transport through inhibition of TRPV5 and TRPV6. Pharmacological Research, 2018, 136, 83-89.	7.1	20
587	Effects of diisononyl phthalate (DiNP) on the endocannabinoid and reproductive systems of male gilthead sea bream (Sparus aurata) during the spawning season. Archives of Toxicology, 2019, 93, 727-741.	4.2	20
588	Antithrombin Chicago, amino acid substitution of arginine 393 to histidine. Thrombosis Research, 1989, 54, 613-619.	1.7	19
589	Rimonabant in rats with a metabolic syndrome: good news after the depression. British Journal of Pharmacology, 2008, 154, 915-917.	5.4	19
590	New Resorcinolâ^'Anandamide "Hybrids―as Potent Cannabinoid Receptor Ligands Endowed with Antinociceptive Activity in Vivo. Journal of Medicinal Chemistry, 2009, 52, 2506-2514.	6.4	19
591	Leucettamols, Bifunctionalized Marine Sphingoids, Act as Modulators of TRPA1 and TRPM8 Channels. Marine Drugs, 2012, 10, 2435-2447.	4.6	19
592	Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at <scp>TRPV1</scp> channels. British Journal of Pharmacology, 2014, 171, 2608-2620.	5.4	19
593	Effect of acyclic monoterpene alcohols and their derivatives on TRP channels. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5507-5511.	2.2	19
594	New horizons on the role of cannabinoid CB1 receptors in palatable food intake, obesity and related dysmetabolism. International Journal of Obesity Supplements, 2014, 4, S26-S30.	12.6	19

#	Article	IF	CITATIONS
595	Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta. Neuropharmacology, 2014, 79, 467-475.	4.1	19
596	Role of Bisphenol A on the Endocannabinoid System at central and peripheral levels: Effects on adult female zebrafish. Chemosphere, 2018, 205, 118-125.	8.2	19
597	The Involvement of the Endocannabinoid System in the Peripheral Antinociceptive Action of Ketamine. Journal of Pain, 2018, 19, 487-495.	1.4	19
598	Development of Potent Inhibitors of Fatty Acid Amide Hydrolase Useful for the Treatment of Neuropathic Pain. ChemMedChem, 2018, 13, 2090-2103.	3.2	19
599	N-palmitoyl-D-glucosamine, A Natural Monosaccharide-Based Glycolipid, Inhibits TLR4 and Prevents LPS-Induced Inflammation and Neuropathic Pain in Mice. International Journal of Molecular Sciences, 2021, 22, 1491.	4.1	19
600	Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition. RSC Advances, 2016, 6, 64651-64664.	3.6	19
601	Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO Journal, 2005, 24, 3517-3518.	7.8	18
602	Iodinated N-Acylvanillamines: Potential "Multiple-Target―Anti-Inflammatory Agents Acting via the Inhibition of T-Cell Activation and Antagonism at Vanilloid TRPV1 Channels. Molecular Pharmacology, 2006, 69, 1373-1382.	2.3	18
603	Palvanil, a non-pungent capsaicin analogue, inhibits inflammatory and neuropathic pain with little effects on bronchopulmonary function and body temperature. Pharmacological Research, 2012, 66, 243-250.	7.1	18
604	Possible involvement of endocannabinoids in the increase of morphine consumption in maternally deprived rat. Neuropharmacology, 2013, 65, 193-199.	4.1	18
605	Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands. European Journal of Medicinal Chemistry, 2015, 90, 526-536.	5.5	18
606	Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3- <i>b</i>]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. Journal of Medicinal Chemistry, 2020, 63, 7369-7391.	6.4	18
607	A histological and chemical study of the cerata of the opisthobranch molluscTethys fimbria. Marine Biology, 1991, 111, 353-358.	1.5	17
608	Dopamides, Vanillylamides, Ethanolamides, and Arachidonic Acid Amides of Antiâ€inflammatory and Analgesic Drug Substances as TRPV1 Ligands. ChemMedChem, 2008, 3, 1956-1964.	3.2	17
609	Conformationally Constrained Fatty Acid Ethanolamides as Cannabinoid and Vanilloid Receptor Probes. Journal of Medicinal Chemistry, 2009, 52, 3001-3009.	6.4	17
610	Biaryl tetrazolyl ureas as inhibitors of endocannabinoid metabolism: Modulation at the N-portion and distal phenyl ring. European Journal of Medicinal Chemistry, 2013, 63, 118-132.	5.5	17
611	Preparation and characterization of Î" ⁹ -tetrahydrocannabinol-loaded biodegradable polymeric microparticles and their antitumoral efficacy on cancer cell lines. Journal of Drug Targeting, 2013, 21, 710-718.	4.4	17
612	Fetal cannabinoid receptors and the "dis-joint-ed" brain. EMBO Journal, 2014, 33, 665-667.	7.8	17

#	Article	IF	CITATIONS
613	Anandamide and decidual remodelling: COX-2 oxidative metabolism as a key regulator. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 1473-1481.	2.4	17
614	Endocannabinoid Tone Regulates Human Sebocyte Biology. Journal of Investigative Dermatology, 2018, 138, 1699-1706.	0.7	17
615	Human leukocytes differentially express endocannabinoid-glycerol lipases and hydrolyze 2-arachidonoyl-glycerol and its metabolites from the 15-lipoxygenase and cyclooxygenase pathways. Journal of Leukocyte Biology, 2019, 106, 1337-1347.	3.3	17
616	Hepatic NAPE-PLD Is a Key Regulator of Liver Lipid Metabolism. Cells, 2020, 9, 1247.	4.1	17
617	Phytocannabinoids promote viability and functional adipogenesis of bone marrow-derived mesenchymal stem cells through different molecular targets. Biochemical Pharmacology, 2020, 175, 113859.	4.4	17
618	Biosynthesis of 2-Arachidonoyl-Glycerol, a Novel Cannabimimetic Eicosanoid, in Mouse Neuroblastoma Cells. Advances in Experimental Medicine and Biology, 1997, 433, 201-204.	1.6	17
619	(Wh)olistic (E)ndocannabinoidome-Microbiome-Axis Modulation through (N)utrition (WHEN) to Curb Obesity and Related Disorders. Lipids in Health and Disease, 2022, 21, 9.	3.0	17
620	In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands. British Journal of Pharmacology, 2006, 149, 431-440.	5.4	16
621	Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors. Bioorganic and Medicinal Chemistry, 2007, 15, 5406-5416.	3.0	16
622	Lipidomic methodologies applicable to the study of endocannabinoids and related compounds: Endocannabinoidomics. European Journal of Lipid Science and Technology, 2009, 111, 53-63.	1.5	16
623	Rapid Combinatorial Access to a Library of 1,5-Disubstituted-3-indole-N-alkylacetamides as CB2 Receptor Ligands. ACS Combinatorial Science, 2009, 11 , $795-798$.	3.3	16
624	1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor. European Journal of Medicinal Chemistry, 2014, 74, 524-532.	5. 5	16
625	Exercise training and high-fat diet elicit endocannabinoid system modifications in the rat hypothalamus and hippocampus. Journal of Physiology and Biochemistry, 2016, 73, 335-347.	3.0	16
626	Endocannabinoids and multiple sclerosis: a blessing from the †inner bliss'?. Trends in Pharmacological Sciences, 2000, 21, 195-197.	8.7	15
627	1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: An effective scaffold for the design of either CB1 or CB2 receptor ligands. European Journal of Medicinal Chemistry, 2011, 46, 5641-5653.	5.5	15
628	Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a) Tj ETQq0 0 0 4-6.	rgBT /Ove 1.4	erlock 10 Tf 5 15
629	Anandamide produced by Ca2+-insensitive enzymes induces excitation in primary sensory neurons. Pflugers Archiv European Journal of Physiology, 2014, 466, 1421-1435.	2.8	15
630	Social defeat leads to changes in the endocannabinoid system: An overexpression of calreticulin and motor impairment in mice. Behavioural Brain Research, 2016, 303, 34-43.	2.2	15

#	Article	IF	Citations
631	Experimental ischemia/reperfusion model impairs endocannabinoid signaling and Na+/K+ ATPase expression and activity in kidney proximal tubule cells. Biochemical Pharmacology, 2018, 154, 482-491.	4.4	15
632	Effects of Dietary Bisphenol A on the Reproductive Function of Gilthead Sea Bream (Sparus aurata) Testes. International Journal of Molecular Sciences, 2019, 20, 5003.	4.1	15
633	Treatment With 2-Pentadecyl-2-Oxazoline Restores Mild Traumatic Brain Injury-Induced Sensorial and Neuropsychiatric Dysfunctions. Frontiers in Pharmacology, 2020, 11, 91.	3.5	15
634	Protective Effects of $\langle i \rangle N \langle i \rangle$ -Oleoylglycine in a Mouse Model of Mild Traumatic Brain Injury. ACS Chemical Neuroscience, 2020, 11, 1117-1128.	3.5	15
635	Anandamide interferes with human endometrial stromalâ€derived cell differentiation: An effect dependent on inhibition of cyclooxygenaseâ€2 expression and prostaglandin E ₂ release. BioFactors, 2016, 42, 277-286.	5.4	15
636	Platelet activating factor-mediated leukotriene biosynthesis in rat lungs: effect of prostaglandins E1 and F1a. Biochemical and Biophysical Research Communications, 1987, 147, 1213-1218.	2.1	14
637	Enantiospecific synthesis of bioactive hydroxyeicosatetraenoic acids (HETEs) in Hydra magnipapillata. Lipids and Lipid Metabolism, 1994, 1213, 215-223.	2.6	14
638	The Endocannabinoid System – Back to the Scene of Cardiometabolic Risk Factors Control?. Hormone and Metabolic Research, 2014, 46, 529-536.	1.5	14
639	Discovery of non-electrophilic capsaicinoid-type TRPA1 ligands. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1009-1011.	2.2	14
640	TRPA1 channels as targets for resveratrol and related stilbenoids. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 899-902.	2.2	14
641	Cannabidiol in sport: Ergogenic or else?. Pharmacological Research, 2020, 156, 104764.	7.1	14
642	Cannabinoids: a class of unique natural products with unique pharmacology. Rendiconti Lincei, 2021, 32, 5-15.	2.2	14
643	Chalcone Derivatives Activate and Desensitize the Transient Receptor Potential Ankyrin 1 Cation Channel, Subfamily A, Member 1 TRPA1 Ion Channel: Structure-Activity Relationships in vitro and Anti-Nociceptive and Anti-inflammatory Activity in vivo. CNS and Neurological Disorders - Drug Targets. 2016. 15. 987-994.	1.4	14
644	New Analgesics Synthetically Derived from the Paracetamol Metabolite $\langle i\rangle N\langle i\rangle - (4-Hydroxyphenyl) - (5\langle i\rangle Z\langle i\rangle, 8\langle i\rangle Z\langle i\rangle, 11\langle i\rangle Z\langle i\rangle, 14\langle i\rangle Z\langle i\rangle) - icosatetra - 5,8,11,14-enamide. Journal of Medicinal Chemistry, 2008, 51, 7800-7805.$	6.4	13
645	Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 610-612.	3.3	13
646	Tetrahydro-Î ² -carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 138-142.	2.2	13
647	Structureâ€"affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. Bioorganic and Medicinal Chemistry, 2014, 22, 4770-4783.	3.0	13
648	Analysis of endocannabinoid signaling elements and related proteins in lymphocytes of patients with Dravet syndrome. Pharmacology Research and Perspectives, 2016, 4, e00220.	2.4	13

#	Article	IF	Citations
649	Arylboronic acids as dual-action FAAH and TRPV1 ligands. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 1401-1405.	2.2	13
650	2-Pentadecyl-2-oxazoline ameliorates memory impairment and depression-like behaviour in neuropathic mice: possible role of adrenergic alpha2- and H3 histamine autoreceptors. Molecular Brain, 2021, 14, 28.	2.6	13
651	Obesity: The Fat Tissue Disease Version of Cancer. Cells, 2022, 11, 1872.	4.1	13
652	Enantioselective synthesis of 3(S)-hydroxy polygodial derivatives and evaluation of their vanilloid activity. Tetrahedron, 2010, 66, 9785-9789.	1.9	12
653	Chronic blockade of CB ₁ receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. British Journal of Pharmacology, 2012, 167, 1652-1664.	5.4	12
654	Role of the endocannabinoid system in obesity induced by neuropeptide Y overexpression in noradrenergic neurons. Nutrition and Diabetes, 2015, 5, e151-e151.	3.2	12
655	Oleoyl glycine: interference with the aversive effects of acute naloxone-precipitated MWD, but not morphine reward, in male Sprague–Dawley rats. Psychopharmacology, 2019, 236, 2623-2633.	3.1	12
656	Acute naloxone-precipitated morphine withdrawal elicits nausea-like somatic behaviors in rats in a manner suppressed by N-oleoylglycine. Psychopharmacology, 2020, 237, 375-384.	3.1	12
657	Role of 2-Arachidonoyl-Glycerol and CB1 Receptors in Orexin-A-Mediated Prevention of Oxygen–Glucose Deprivation-Induced Neuronal Injury. Cells, 2020, 9, 1507.	4.1	12
658	Desensitization of transient receptor potential vanilloid type-1 (TRPV1) channel as promising therapy of irritable bowel syndrome: characterization of the action of palvanil in the mouse gastrointestinal tract. Naunyn-Schmiedeberg's Archives of Pharmacology, 2020, 393, 1357-1364.	3.0	12
659	Adverse effects of î"9-tetrahydrocannabinol on neuronal bioenergetics during postnatal development. JCI Insight, 2020, 5, .	5.0	12
660	Exploring the endocannabinoidome in genetically obese (ob/ob) and diabetic (db/db) mice: Links with inflammation and gut microbiota. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159056.	2.4	12
661	Neuropeptides and inflammatory mediators: bidirectional regulatory mechanisms. Trends in Pharmacological Sciences, 1989, 10, 91-92.	8.7	11
662	The synthesis, release and action of leukotrienes in the isolated, unstimulated, buffer-perfused rat heart. Journal of Molecular and Cellular Cardiology, 1989, 21, 1101-1110.	1.9	11
663	Prostaglandin F-1,15-lactone fatty acyl esters: a prostaglandin lactone pathway branch developed during the reproduction and early larval stages of a marine mollusc. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1992, 101, 99-104.	0.2	11
664	Homologues and isomers of noladin ether, a putative novel endocannabinoid: interaction with rat cannabinoid CB1 receptors. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 43-46.	2.2	11
665	Why fasting worms age slowly. Nature, 2011, 473, 161-162.	27.8	11
666	Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration. Journal of Cellular Physiology, 2015, 230, 2905-2914.	4.1	11

#	Article	IF	CITATIONS
667	Plasma palmitoylethanolamide (PEA) as a potential biomarker for impaired coronary function. International Journal of Cardiology, 2017, 231, 1-5.	1.7	11
668	The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil. Lipids in Health and Disease, 2017, 16, 16.	3.0	11
669	Hedonic eating in Prader–Willi syndrome is associated with blunted PYY secretion. Food and Nutrition Research, 2017, 61, 1297553.	2.6	11
670	Effects of repeated longâ€term psychosocial stress and acute cannabinoid exposure on mouse corticostriatal circuitries: Implications for neuropsychiatric disorders. CNS Neuroscience and Therapeutics, 2018, 24, 528-538.	3.9	11
671	Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists. Journal of Medicinal Chemistry, 2018, 61, 8255-8281.	6.4	11
672	In Silico Identification and Experimental Validation of (â^')-Muqubilin A, a Marine Norterpene Peroxide, as PPARα/γ-RXRα Agonist and RARα Positive Allosteric Modulator. Marine Drugs, 2019, 17, 110.	4.6	11
673	Design, Synthesis and In Vitro Experimental Validation of Novel TRPV4 Antagonists Inspired by Labdane Diterpenes. Marine Drugs, 2020, 18, 519.	4.6	11
674	Oleoyl alanine (HU595): a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats. Psychopharmacology, 2020, 237, 2753-2765.	3.1	11
675	Genetic Manipulation of sn-1-Diacylglycerol Lipase and CB ₁ Cannabinoid Receptor Gain-of-Function Uncover Neuronal 2-Linoleoyl Glycerol Signaling in <i>Drosophila melanogaster</i> Cannabis and Cannabinoid Research, 2021, 6, 119-136.	2.9	11
676	Orexin-A/Hypocretin-1 Controls the VTA-NAc Mesolimbic Pathway via Endocannabinoid-Mediated Disinhibition of Dopaminergic Neurons in Obese Mice. Frontiers in Synaptic Neuroscience, 2021, 13, 622405.	2.5	11
677	Biosynthesis of the Novel Endogenous 15-Lipoxygenase Metabolites N-13-Hydroxy-octodecadienoyl-ethanolamine and 13-Hydroxy-octodecadienoyl-glycerol by Human Neutrophils and Eosinophils. Cells, 2021, 10, 2322.	4.1	11
678	Amygdalar CB2 cannabinoid receptor mediates fear extinction deficits promoted by orexin-A/hypocretin-1. Biomedicine and Pharmacotherapy, 2022, 149, 112925.	5.6	11
679	New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 138-141.	2.2	10
680	Metabolically labile cannabinoid esters: A †soft drug†approach for the development of cannabinoid-based therapeutic drugs. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 4878-4881.	2.2	10
681	Placebo Effects in a Multiple Sclerosis Spasticity Enriched Clinical Trial with the Oromucosal Cannabinoid Spray (<scp>THC</scp> / <scp>CBD</scp>): Dimension and Possible Causes. CNS Neuroscience and Therapeutics, 2015, 21, 215-221.	3.9	10
682	Role of the endocannabinoid system in the control of mouse myometrium contractility during the menstrual cycle. Biochemical Pharmacology, 2017, 124, 83-93.	4.4	10
683	Development of a Rapid LC-MS/MS Method for the Quantification of Cannabidiol, Cannabidivarin, î" ⁹ -Tetrahydrocannabivarin, and Cannabigerol in Mouse Peripheral Tissues. Analytical Chemistry, 2017, 89, 4749-4755.	6.5	10
684	Targeting fatty acid amide hydrolase and transient receptor potential vanilloidâ€1 simultaneously to modulate colonic motility and visceral sensation in the mouse: A pharmacological intervention with Nâ€arachidonoylâ€serotonin (<scp>AA</scp> â€5â€ <scp>HT</scp>). Neurogastroenterology and Motility, 2017, 29, e13148.	3.0	10

#	Article	IF	Citations
685	Biological basis of cannabinoid medicines. Science, 2021, 374, 1449-1450.	12.6	10
686	Influence of diet on acute endocannabinoidome mediator levels post exercise in active women, a crossover randomized study. Scientific Reports, 2022, 12 , .	3.3	10
687	Neuropeptides and leukotriene release: Effect of peptide histidine isoleucine and secretin in platelet activating factor-stimulated rat lung. Neuropeptides, 1987, 9, 51-58.	2.2	9
688	Arachidonic acid as an endogenous signal for the glutathione-induced feeding response in Hydra. Cellular and Molecular Life Sciences, 1997, 53, 61-68.	5.4	9
689	Chemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide. Journal of Lipid Research, 2009, 50, 658-666.	4.2	9
690	Cannabidiol improves vocal learning-dependent recovery from, and reduces magnitude of deficits following, damage to a cortical-like brain region in a songbird pre-clinical animal model. Neuropharmacology, 2019, 158, 107716.	4.1	9
691	Spontaneous and Naloxone-Precipitated Withdrawal Behaviors From Chronic Opiates are Accompanied by Changes in N-Oleoylglycine and N-Oleoylalanine Levels in the Brain and Ameliorated by Treatment With These Mediators. Frontiers in Pharmacology, 2021, 12, 706703.	3.5	9
692	The endocannabinoid system for the development of new drugs for spasticity. Drugs of the Future, 2007, 32, 0341.	0.1	9
693	Alterations of the endocannabinoid system and circulating and peripheral tissue levels of endocannabinoids in sarcopenic rats. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 662-676.	7.3	9
694	Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia. Biomolecules, 2022, 12, 108.	4.0	9
695	The role of cyclic AMP in the inhibition of leukotriene biosynthesis by neuropeptides. European Journal of Pharmacology, 1989, 162, 115-121.	3.5	8
696	The effect of diterpenoidic diacylglycerols on tentacle regeneration in Hydra vulgaris. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1991, 100, 603-607.	0.2	8
697	Anandamide-loaded nanoparticles: Preparation and characterization. Journal of Microencapsulation, 2011, 28, 200-210.	2.8	8
698	Endocannabinoid-dependent disinhibition of orexinergic neurons: Electrophysiological evidence in leptin-knockout obese mice. Molecular Metabolism, 2017, 6, 594-601.	6.5	8
699	Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis. Journal of Immunology Research, 2019, 2019, 1-14.	2.2	8
700	Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation. Biomolecules, 2021, 11, 1134.	4.0	8
701	Cannabinoid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	8
702	Mutual Links between the Endocannabinoidome and the Gut Microbiome, with Special Reference to Companion Animals: A Nutritional Viewpoint. Animals, 2022, 12, 348.	2.3	8

#	Article	IF	CITATIONS
703	Adipocyte-specific Nos2 deletion improves insulin resistance and dyslipidemia through brown fat activation in diet-induced obese mice. Molecular Metabolism, 2022, 57, 101437.	6.5	8
704	Manipulation of the endocannabinoid system by a general anaesthetic. British Journal of Pharmacology, 2003, 139, 885-886.	5.4	7
705	Enantioselective synthesis and vanilloid activity evaluation of $1 \cdot \hat{l}^2$ -(p-methoxycinnamoyl)polygodial, an antinociceptive compound from Drymis winteri barks. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6444-6447.	2.2	7
706	Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands. European Journal of Medicinal Chemistry, 2010, 45, 5878-5886.	5 . 5	7
707	Cannabinoids in the Treatment of Neurological Disorders. Neurotherapeutics, 2015, 12, 689-691.	4.4	7
708	Techniques for the Cellular and Subcellular Localization of Endocannabinoid Receptors and Enzymes in the Mammalian Brain. Methods in Enzymology, 2017, 593, 61-98.	1.0	7
709	Oral Capsaicinoid Administration Alters the Plasma Endocannabinoidome and Fecal Microbiota of Reproductive-Aged Women Living with Overweight and Obesity. Biomedicines, 2021, 9, 1246.	3.2	7
710	Endocannabinoids in the new millennium. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 66, 91-92.	2.2	6
711	Synthesis, conformational analysis and CB1 binding affinity of hairpin-like anandamide pseudopeptide mimetics. Journal of Peptide Science, 2006, 12, 575-591.	1.4	6
712	Enantioselective synthesis of 1-(R)-hydroxypolygodial and its $9\hat{l}_{\pm}$ epimer, 1-(R)-hydroxyisotadeonal. Tetrahedron, 2007, 63, 6866-6873.	1.9	6
713	Resorcinol- <i>sn</i> -Glycerol Derivatives: Novel 2-Arachidonoylglycerol Mimetics Endowed with High Affinity and Selectivity for Cannabinoid Type 1 Receptor. Journal of Medicinal Chemistry, 2011, 54, 8278-8288.	6.4	6
714	"De-liver-ance―From CB1: A Way to Counteract Insulin Resistance?. Gastroenterology, 2012, 142, 1063-1066.	1.3	6
715	Inhibitory effect of positively charged triazine antagonists of prokineticin receptors on the transient receptor vanilloid type-1 (TRPV1) channel. Pharmacological Research, 2015, 99, 362-369.	7.1	6
716	Linking the Endocannabinoidome with Specific Metabolic Parameters in an Overweight and Insulin-Resistant Population: From Multivariate Exploratory Analysis to Univariate Analysis and Construction of Predictive Models. Cells, 2021, 10, 71.	4.1	6
717	<i>N</i> â€Acylethanolamine acid amidase (NAAA) is dysregulated in colorectal cancer patients and its inhibition reduces experimental cancer growth. British Journal of Pharmacology, 2022, 179, 1679-1694.	5.4	6
718	Arachidonic acid, protein kinase C activators and bud formation in Hydra vulgaris. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1993, 105, 219-224.	0.2	5
719	Phospholipase A2 and protein kinase C enzymatic activities and their interactions in Hydra vulgaris. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1995, 111, 211-219.	1.6	5
720	Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction. Expert Review of Neurotherapeutics, 2011, 11, 9-14.	2.8	5

#	Article	IF	Citations
721	Impact of omegaâ€6 polyunsaturated fatty acid supplementation and γâ€aminobutyric acid on astrogliogenesis through the endocannabinoid system. Journal of Neuroscience Research, 2013, 91, 943-953.	2.9	5
722	Naphthalene and 2,3-dihydrobenzo[b][1,4]dioxine derivatives with extended side chains as new scaffolds of CB2-selective ligands. MedChemComm, 2014, 5, 1571-1576.	3.4	5
723	N-Oleoylglycine and N-Oleoylalanine Do Not Modify Tolerance to Nociception, Hyperthermia, and Suppression of Activity Produced by Morphine. Frontiers in Synaptic Neuroscience, 2021, 13, 620145.	2.5	5
724	Maternal omega-3 intake differentially affects the endocannabinoid system in the progeny's neocortex and hippocampus: Impact on synaptic markers. Journal of Nutritional Biochemistry, 2021, 96, 108782.	4.2	5
725	\hat{l}^2 -Endorphin in Neoroblastoma x Glioma hybrid cells. Neuropeptides, 1985, 6, 53-57.	2.2	4
726	Neuropeptides and leukotriene biosynthesis: The effect of calcitonin, peptide histidine valine-42, helodermin, neuropeptide Y and galanin. Neuropeptides, 1988, 11, 169-172.	2.2	4
727	Hydra vulgaris ï‰10-lipoxygenase is used in vivo to synthesize new α-linolenic acid metabolites. Experientia, 1995, 51, 48-56.	1,2	4
728	Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action, by V. Di Marzo, D. Melck, T. Bisogno and L. De Petrocellis, Vol. 21, pp. 521–528 Trends in Neurosciences, 1999, 22, 80.	8.6	4
729	Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs. Expert Opinion on Therapeutic Targets, 2001, 5, 349-362.	3.4	4
730	Endocannabinoid system and its role in energy regulation. Expert Review of Endocrinology and Metabolism, 2006, 1, 557-569.	2.4	4
731	The endocannabinoid system in metabolic control: a preface. Best Practice and Research in Clinical Endocrinology and Metabolism, 2009, 23, vii-ix.	4.7	4
732	Alteration of the endocannabinoid system in mouse brain during prion disease. Neuroscience, 2011, 177, 292-297.	2.3	4
733	Sex-dependent effects of neonatal maternal deprivation on endocannabinoid levels in the adipose tissue: influence of diet. Journal of Physiology and Biochemistry, 2016, 73, 349-357.	3.0	4
734	Intuitive eating is associated with elevated levels of circulating omega-3-polyunsaturated fatty acid-derived endocannabinoidome mediators. Appetite, 2021, 156, 104973.	3.7	4
735	Synthesis and molecular targets of N-13-hydroxy-octadienoyl-ethanolamine, a novel endogenous bioactive 15-lipoxygenase-derived metabolite of N-linoleoyl-ethanolamine found in the skin and saliva. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2021, 1866, 158954.	2.4	4
736	Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model. Nutrients, 2021, 13, 4218.	4.1	4
737	Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis. International Journal of Molecular Sciences, 2021, 22, 12361.	4.1	4
738	Native opioid-like peptides in Squilla mantis ganglia. Peptides, 1985, 6, 403-406.	2.4	3

#	Article	IF	Citations
739	RIA/chromatographic evidence for novel opioid peptide(s) in ganglia. Neuropeptides, 1986, 7, 281-289.	2.2	3
740	\H i% 10-Lipoxygenase products of \H i±-linolenic acid are esterified to phospholipids inHydra vulgaris. Experientia, 1996, 52, 120-126.	1.2	3
741	Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. Life Sciences, 2004, 76, 461-472.	4.3	3
742	Structure-Based Virtual Screening: Identification of Novel CB2 Receptor Ligands. Letters in Drug Design and Discovery, 2007, 4, 15-19.	0.7	3
743	Effect of narrowband ultraviolet B treatment on endocannabinoid plasma levels in patients with psoriasis. British Journal of Dermatology, 2014, 171, 198-201.	1.5	3
744	N-Acyldopamines and N-Acylserotonins: From Synthetic Pharmacological Tools to Endogenous Multitarget Mediators. , 2015 , , 67 - 84 .		3
745	Targeted Lipidomics Investigation of <i>N</i> â€ecylethanolamines in a Transgenic Mouse Model of AD: A Longitudinal Study. European Journal of Lipid Science and Technology, 2019, 121, 1900015.	1.5	3
746	Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity. Bioorganic and Medicinal Chemistry, 2020, 28, 115513.	3.0	3
747	The Endocannabinoid System in Leptin-Driven Changes of Orexinergic Signaling Under Physiological and Pathological Conditions., 2017,, 1-26.		3
748	Human and Mouse Eosinophils Differ in Their Ability to Biosynthesize Eicosanoids, Docosanoids, the Endocannabinoid 2-Arachidonoyl-glycerol and Its Congeners. Cells, 2022, 11, 141.	4.1	3
749	The effect of a cAMP analogue on Ca2+ ionophore-, antigen- and agonist-induced inositol phosphate release in rat basophilic leukemia (RBL-1) cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1992, 1133, 218-222.	4.1	2
750	Biosynthesis of hydroxyeicosatetraenoic acids (HETEs) in marine and freshwater hydroids. Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1993, 106, 901-906.	0.2	2
751	Editorial [Hot Topic: New Potential Therapies from Vanilloid Transient Receptor Cation (TRPV) Channels (Executive Editors: V. Di Marzo and K. Starowicz)]. Current Pharmaceutical Design, 2008, 14, 1-1.	1.9	2
752	FAAH-Catalyzed C–C Bond Cleavage of a New Multitarget Analgesic Drug. ACS Chemical Neuroscience, 2019, 10, 424-437.	3.5	2
7 53	$\hat{l}\pm 2$ -Adrenoceptor agonist induces peripheral antinociception via the endocannabinoid system. Pharmacological Reports, 2020, 72, 96-103.	3.3	2
754	A Glucuronic Acid-Palmitoylethanolamide Conjugate (GLUPEA) Is an Innovative Drug Delivery System and a Potential Bioregulator. Cells, 2021, 10, 450.	4.1	2
755	Deletion of the gene encoding prostamide/prostaglandin F synthase reveals an important role in regulating intraocular pressure. Prostaglandins Leukotrienes and Essential Fatty Acids, 2021, 165, 102235.	2.2	2
756	Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock?. Cannabis and Cannabinoid Research, 2023, 8, 5-11.	2.9	2

#	Article	IF	CITATIONS
757	PAF-mediated leukotriene biosynthesis in lungs : Control by the neuropeptidergic system. Prostaglandins, 1987, 34, 185.	1.2	1
758	Targeted lipidomics: endocannabinoids and other endolipid modulators. Life Sciences, 2005, 77, 1517-1518.	4.3	1
759	Synthesis and binding study of certain 6-arylalkanamides as molecular probes for cannabinoid receptor subtypes. Journal of Enzyme Inhibition and Medicinal Chemistry, 2013, 28, 436-439.	5. 2	1
760	Editorial. Recent Patents on CNS Drug Discovery, 2013, 8, 1-1.	0.9	1
761	Sullay Small intestine epithelial organoids as a model to investigate the role of the endocannabinoidome on intestinal paracellular permeability during inflammation. Gastroenterology, 2020, 158, S-516.	1.3	1
762	Endocannabinoids in Energy Homeostasis and Metabolic Disorders. , 2008, , 277-316.		1
763	Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors. , 2013, , 175-197.		1
764	Kahweol, a natural diterpene from coffee, induces peripheral antinociception by endocannabinoid system activation. Brazilian Journal of Medical and Biological Research, 2021, 54, e11071.	1.5	1
765	Anandamide and other cannabimimetic fatty acid derivativesâ€"foreword. Prostaglandins and Other Lipid Mediators, 2000, 61, 1-2.	1.9	O
766	Corrigendum to Halogenation of a capsaicin analogue leads to novel vanilloid TRPVI receptor antagonists. British Journal of Pharmacology, 2003, 140, 1008-1008.	5.4	0
767	Novel mechanisms in obesity, type 2 diabetes and accompanying inflammation: focus on lipid signaling. Drug Discovery Today Disease Mechanisms, 2010, 7, e159-e161.	0.8	O
768	Questions & Answers. Expert Review of Neurotherapeutics, 2011, 11, 21-22.	2.8	0
769	TRPV1 modulators: Synthesis and inÂvitro evaluation of 1-heteroaryl piperidinecarboxamide and piperazinylurea derivatives. European Journal of Medicinal Chemistry, 2015, 100, 129-138.	5.5	0
770	The ever-expanding world of the endocannabinoids: A concise introduction. , 2015, , xxv-xlv.		0
771	Tu1205 OBESITY-RELATED ENDOGENOUS MICROENVIRONMENT IMPACTS INSULIN SIGNALING AND INTESTINAL FUNCTIONS OF INTESTINAL ORGANOIDS. Gastroenterology, 2020, 158, S-1018.	1.3	О
772	Editorial on "Cannabis and cannabinoids: history, practice and socio-economical inferences of a controversial plant― Rendiconti Lincei, 2021, 32, 1-4.	2.2	0
773	A Designer Diet Induces Thermogenic Adipocytes <i>via</i> Raptor and Prolongs Healthy Lifespan. SSRN Electronic Journal, 0, , .	0.4	O
774	Endocannabinoids., 2020, , 1-9.		0

į	#	Article	IF	CITATIONS
	775	Endocannabinoids., 2021,, 597-605.		0
	776	Facile and Sustainable Synthesis of Commendamide and its Analogues. Frontiers in Chemistry, 2022, 10, 858854.	3.6	0